Vanta Bioscience Limited

Regd. Office : 1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, INDIA.
Tel : +91 40 6657 5454, 2790 3226
Fax : +91 40 2790 8708
Website : www.vantabio.com
Email : info@vantabio.com
CIN No. : L74999TG2016PLC109280

21.09.2026
Hyderabad

To
Corporate Compliance Dept.
BSE Limited,
P.J. Towers, Dalal Street,
Mumbai – 400001, Maharashtra

Sub: Submission of Annual Report for the financial year 2025-26
Ref: Scrip Code: 540729 | Scrip ID: VANTABIO

Dear Sir/Madam,

Pursuant to Regulation 34 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the Notice of the 10th Annual General Meeting ("AGM") of the Company along with the Annual Report for the Financial Year 2025-26. The same has also been uploaded on the Company's website.

This is for your information and for dissemination to general public.

Thanking you,
for VANTA BIOSCIENCE LIMITED

MULAKALA
DOPESH
RAJA

Digitally signed by
MULAKALA DOPESH
RAJA
Date: 2026.09.21
13:59:11 +05'30'

DOPESH RAJA MULAKALA
MANAGING DIRECTOR
DIN: 01176660

Encl: As above

VANTA
BIOSCIENCE LIMITED

SCIENCE
FOR A
HEALTHIER
TOMORROW

RESEARCH
INNOVATION
BETTER HEALTH
BRIGHTER LIVES

10th ANNUAL REPORT
2025-26

Vanta Bioscience Limited

10th Annual Report
FY 2025-26

Wednesday, September 30, 2026 at 10:00 A.M.

At 197, Arun Khetarpal Road, Uma Nagar Colony,
Sikh Village, Bowenpally, Secunderabad - 500009,
Telangana, India.

Table of Contents

CORPORATE INFORMATION

Board of Directors

Mr. Dopesh Raja Mulakala (DIN: 01176660) : Managing Director
Dr. Padmanabhuni Venkata Appaji (DIN: 02614167) : Non-Executive Independent Director
Dr. Gonuguntla Kathyayani (DIN: 07824881) : Non-Executive Independent Director
Dr. Yogeswara Rao Danda (DIN: 00694803) : Non-Executive Independent Director

KMPs

Mr. Dokka Venkata Sathya Murali : Chief Financial Officer
Ms. Pooja Kothari : Company Secretary & Compliance Officer

Registered Office

Vanta Bioscience Limited
No.02/G/308/G, No.3/FF/SF/1-20-248, Umajay Complex,
Rasoolpura, Secunderabad - 500 003, Telangana, India
CIN: L74999TG2016PLC109280 | Website: www.vantabio.com
Contact No.: +91 40 6657 5454 | Email ID: cs@vantabio.com
ISIN: INE695X01011

Statutory Auditors

Mathesh & Ramana
Chartered Accountants
3-6-145, Himayatnagar,
Hyderabad – 500 029, Telangana

Secretarial Auditors

Ms. Putcha Sarada
Practicing Company Secretary
Hyderabad, Telangana

Bankers

State Bank of India
SME Branch, Saifabad,
Hyderabad – 500 004, Telangana

Registrar & Share Transfer Agents

Bigshare Services Private Limited
306, Right Wing, Amrutha Ville Apts.,
Somajiguda, Hyderabad – 500 082
Contact No. : 040 2337 4967
E-Mail :bsshyd@bigshareonline.com

Listed at

SME Platform of BSE Ltd.
Scrip Code: 540729 | Scrip ID: VANTABIO

VANTA BIOSCIENCE LIMITED
Regd. Office: No.02/G/308/G, No.3/FF/SF/1-20-248, Umajay Complex,
Rasoolpura, Secunderabad – 500 003, Telangana, India
CIN: L74999TG2016PLC109280| **Website:** www.vantabio.com
Contact No.: +91 40 6657 5454|**Email ID:** cs@vantabio.com

NOTICE

Notice is hereby given that the 10th Annual General Meeting of the Shareholders of Vanta Bioscience Limited will be held on Wednesday, September 30, 2026 at 10:00 AM at 197, Arun Khetarpal Road, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad - 500009, Telangana, to transact the following businesses:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026 along with the Reports of the Auditors and Board of Directors thereon.
2. To appoint a director in place of Mr. Dopesh Raja Mulakala (DIN: 01176660), Managing Director of the Company, who retires by rotation and being eligible, offers himself for re-appointment.

Special Business:

3. **Re-appointment of Mr. Dopesh Raja Mulakala (DIN: 01176660) as Managing Director of the Company**

   To consider and, if thought fit, to pass the following resolution as an **Ordinary Resolution**:

   RESOLVED THAT pursuant to the provisions of Sections 196, 197, 203 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Schedule V of the Companies Act, 2013, pursuant to the recommendation of Nomination and Remuneration Committee and subject to necessary approvals, if any, the consent of the members be and is hereby accorded for the re-appointment of Mr. Dopesh Raja Mulakala (DIN: 01176660) as the Managing Director of the Company for another term of 3 years with effect from April 18, 2026 at a remuneration detailed below:

   i) Overall remuneration: Mr. Dopesh Raja Mulakala (DIN: 01176660) may be paid a remuneration (i.e. salary, perquisites and commission) upto Rs. 2,50,000/- (Rupees Two Lakh and Fifty Thousand Only) per month as may be decided by the Board. He shall also be provided with a Company car with driver, telephone instrument and a laptop and shall be eligible for reimbursement of expenses at actuals in accordance with the policy of the Company. In case of any doubts/discrepancy/clarification that may arise with respect to payment of remuneration the same shall be determined and decided by the Board.

   ii) Minimum remuneration: In the event of inadequacy or absence of profits in any financial year, during the currency of the tenure of his office, he shall be paid the above remuneration, as minimum remuneration in accordance with the provisions of Part II of Schedule V of the Act.

   iii) The Board shall have the discretion to determine whether any remuneration shall be payable to Mr. Dopesh Raja Mulakala (DIN: 01176660) during the tenure of his appointment and, if so payable, to determine, revise, modify or vary from time to time the amount, composition, structure, mode and terms of payment thereof, subject to the provisions of the Companies Act, 2013 and such approvals as may be required.

   RESOLVED FURTHER THAT the Directors of the Company be and are hereby severally authorised to do all such acts things and deeds including but not limited to filing of requisite forms/ returns with the office of Registrar of Companies so as to bring this resolution into force."

By order of the Board
For Vanta Bioscience Limited

Sd/-
Dopesh Raja Mulakala
Managing Director
DIN: 01176660

05.09.2026
Secunderabad

NOTICE

1. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY.** The Proxy form duly filled in should be deposited at the Registered Office of the Company not less than 48 hours before the commencement of the Meeting. All alterations/corrections made in the form of Proxy should be initialled by the Member.

2. Members are requested to bring their attendance slip along with their copy of Annual Report to the Meeting. Corporate members intending to send their authorised representatives to attend the meeting are requested to send to the company a certified copy of the Board resolution authorising their representative to attend and vote on their behalf at the meeting.

3. In case of joint holders attending the Meeting, only such joint holders who are higher in the order of names will be entitled to vote.

4. Relevant documents referred to in the accompanying Notice and the Statement are open for inspection by the members at the Registered Office of the Company on all working days, except Sundays, during business hours upto the date of the Annual General Meeting.

5. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their Demat accounts.

   Members are requested to mandatorily quote their Registered Folio No. or Demat Account No. and Depository Participant Identification Number (DPID No) on all correspondence with the company. Securities and Exchange Board of India [SEBI] has mandated that securities of Listed Companies can be transferred only in dematerialised form with effect from April 1, 2019.

6. Members are advised to update their email IDs with Company's RTA and/or concerned Depository participants as soon as possible.

7. Details of Directors seeking appointment / re-appointment in forthcoming Annual General Meeting In pursuance of Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard on General Meetings.

8. As per Secretarial Standards 2 (SS-2), complete particulars of the venue of the Meeting (route map) has been attached herewith to the Notice.

9. **Remote e -Voting**

   The items of business as set out in the Notice may be transacted through electronic voting system. Therefore, the Company is providing facility for voting by electronic means. Pursuant to Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time and in force as on date and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company is pleased to offer remote e-voting facility, as an alternate, to its members in respect of the business to be transacted at the AGM.

   The Members, whose names appear in the Register of Members / list of Beneficial Owners as on Wednesday, September 23, 2026 are entitled to vote on the resolutions set forth in this Notice. Eligible members who have acquired shares after the dispatch of the Annual Report may approach the Company for required assistance in connection with generation of the User ID / Password in order to exercise their right to vote by electronic means. The remote e-voting period will commence at 9.00 A.M. on Sunday, September 27, 2026 and will end at 5.00 P.M. on Tuesday, September 29, 2026. The members will not be able to cast their votes electronically beyond the date and time mentioned above.

   The Company has appointed Mr. Zoheb Sayani, Practicing Company Secretary (Membership. No. F10881 and C.P No.26128) to act as a Scrutinizer to conduct and scrutinize the voting process in a fair and transparent manner.

   The Members desiring to vote through electronic mode may refer to the detailed procedure on remote e-voting given hereunder:

THE INSTRUCTIONS FOR SHAREHOLDERS FOR REMOTE E-VOTING ARE AS UNDER:

Step 1 : Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

Step 2 : Access through CDSL e-Voting system in case of non-individual shareholders in demat mode.

(i) The voting period begins on **9.00 A.M. on Sunday, September 27, 2026 and will end at 5.00 P.M. on Tuesday, September 29, 2026**. During this period shareholders' of the Company, holding shares in dematerialized form, as on the cut-off date (record date) of **Wednesday, September 23, 2026** may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.

(ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.

(iii) Pursuant to SEBI Circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated 09.12.2020, under Regulation 44 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, listed entities are required to provide remote e-voting facility to its shareholders, in respect of all shareholders' resolutions. However, it has been observed that the participation by the public non-institutional shareholders/retail shareholders is at a negligible level.

Currently, there are multiple e-voting service providers (ESPs) providing e-voting facility to listed entities in India. This necessitates registration on various ESPs and maintenance of multiple user IDs and passwords by the shareholders.

In order to increase the efficiency of the voting process, pursuant to a public consultation, it has been decided to enable e-voting to all the demat account holders, by way of a single login credential, through their demat accounts/ websites of Depositories/ Depository Participants. Demat account holders would be able to cast their vote without having to register again with the ESPs, thereby, not only facilitating seamless authentication but also enhancing ease and convenience of participating in e-voting process.

Step 1: Access through Depositories CDSL/NSDL e-Voting system in case of individual shareholders holding shares in demat mode.

(iv) In terms of SEBI circular **no. SEBI/HO/CFD/CMD/CIR/P/2020/242** dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for e-Voting **for Individual shareholders holding securities in Demat mode CDSL/NSDL** is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with **CDSL Depository**	1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The users to login to Easi / Easiest are requested to visit cdsl website www.cdslindia.com and click on login icon & New System Myeasi Tab. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at cdsl website www.cdslindia.com and click on login & New System Myeasi Tab and then click on registration option. 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

Type of shareholders	Login Method
Individual Shareholders holding securities in demat mode with **NSDL Depository**	1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsdl.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the "Beneficial Owner" icon under "Login" which is available under 'IDeAS' section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on "Access to e-Voting" under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsdl.com. Select "Register Online for IDeAS "Portal or click at https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsdl.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period. For OTP based login you can click on https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp. You will have to enter your 8-digit DP ID,8-digit Client Id, PAN No., Verification code and generate OTP. Enter the OTP received on registered email id/mobile number and click on login. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. NSDL Mobile App is available on App Store Google Play
Individual Shareholders (holding securities in demat mode) login through their **Depository Participants (DP)**	You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period.

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. CDSL and NSDL

Login type	Helpdesk details
Individual Shareholders holding securities in Demat mode with **CDSL**	Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911
Individual Shareholders holding securities in Demat mode with **NSDL**	Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at : 022 - 4886 7000 and 022 - 2499 7000

Step 2: Access through CDSL e-Voting system in case of non-individual shareholders in demat mode.

(v) Login method for Remote e-Voting for **shareholders other than individual holding in Demat form**.

1) The shareholders should log on to the e-voting website www.evotingindia.com.

2) Click on "Shareholders" module.

3) Now enter your User ID
   a. For CDSL: 16 digits beneficiary ID,
   b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,

4) Next enter the Image Verification as displayed and Click on Login.

5) If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

6) If you are a first-time user follow the steps given below:

	individual shareholders holding shares in Demat
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department • Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details **OR** Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. • If both the details are not recorded with the depository or company, please enter the member id / folio number in the Dividend Bank details field.

(vi) After entering these details appropriately, click on "SUBMIT" tab.

(vii) Shareholders holding shares in physical form will then directly reach the Company selection screen. Shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

(viii) Click on the EVSN for the relevant <VANTA BIOSCIENCE LIMITED> on which you choose to vote.

(ix) On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

(x) Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.

(xi) After selecting the resolution, you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.

(xii) Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.

(xiii) You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.

(xiv) If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(xv) There is also an optional provision to upload BR/POA if any uploaded, which will be made available to scrutinizer for verification.

(xvi) **Additional Facility for Non – Individual Shareholders and Custodians –For Remote Voting only.**

- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
- A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.

- After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
- The list of accounts linked in the login will be mapped automatically & can be delinked in case of any wrong mapping.
- It is Mandatory that, a scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
- Alternatively Non Individual shareholders are required mandatory to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; cs@vantabio.com, if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.

PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.

1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to cs@vantabio.com.
2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

If you have any queries or issues regarding e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 21 09911

All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call at toll free no. 1800 21 09911. Please contact the company at cs@vantabio.com in case of any queries.

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013

Item No. 3 - Re-appointment of Mr. Dopesh Raja Mulakala as Managing Director

Mr. Dopesh Raja Mulakala (DIN: 01176660) has been associated with the Company since its incorporation and is presently the Managing Director and Promoter of the Company. His previous term as Managing Director was for a period of three years from 18.04.2023 to 17.04.2026, as approved by the Members at the 7th Annual General Meeting held on 30.09.2023.

The Board of Directors, at its meeting held on 30.05.2026, approved his re-appointment as Managing Director for a further period of three years with effect from 18.04.2026 subject to the approval of the Members and other applicable requirements.

Mr. Dopesh Raja Mulakala (DIN: 01176660) holds an MBA from Case Western Reserve University, U.S.A. and has substantial experience in setting up and managing businesses in the manufacturing and research & development sectors. The Board considers that his continued leadership would be in the interest of the Company.

Mr. Dopesh Raja Mulakala (DIN: 01176660) is interested in the resolution relating to his re-appointment. Save and except him and his relatives and to the extent of their shareholding interest, none of the other Directors or Key Managerial Personnel of the Company or their relatives are, in any way, concerned or interested, financially or otherwise, in the said resolution. The Board recommends the Ordinary Resolution set out at Item No. 3 of the Notice for approval of the Members.

Additional Disclosure in terms of Section II of Part II of Schedule V of the Companies Act, 2013 in relation to Item No. 3

<table>
<tr><th colspan="5">I. GENERAL INFORMATION</th></tr>
<tr><td>Nature of Industry</td><td colspan="4">The Company is engaged in the business of providing research and development and a range of preclinical safety assessment services, including in-vitro and in-vivo toxicology studies, catering to pharmaceutical, agrochemical, food, cosmetics, medical devices and other allied industries.</td></tr>
<tr><td>Date of commencement of commercial operation</td><td colspan="4">The Company has already commenced its commercial operations in FY 2017-18.</td></tr>
<tr><td>In case of new Company, expected dateof Commencement of activities as per project approved by FI, appearing in the prospectus</td><td colspan="4">Not Applicable, since the Company is an existing Company and has already commenced its commercial operations.</td></tr>
<tr><td rowspan="6">Financial Performance</td><td colspan="4">Rs. in Thousands</td></tr>
<tr><td>Financial parameters</td><td>FY 2025-26</td><td>FY 2024-25</td><td>FY 2023-24</td></tr>
<tr><td>Turnover (operational revenue)</td><td>18,163.64</td><td>11,274.22</td><td>85,579.11</td></tr>
<tr><td>Net profit after tax</td><td>1,198.11</td><td>(26,594.08)</td><td>510.52</td></tr>
<tr><td>Amount of dividend paid</td><td>-</td><td>-</td><td>-</td></tr>
<tr><td>Rate of dividend declared</td><td>-</td><td>-</td><td>-</td></tr>
<tr><td>Foreign Investments or collaborations</td><td colspan="4">Nil. The Company does not have any foreign investment or foreign collaboration. However, NRIs may hold shares of the Company acquired through the stock market.</td></tr>
<tr><th colspan="5">II. INFORMATION ABOUT THE APPOINTEE</th></tr>
<tr><td>Background Details</td><td colspan="4">Mr. Dopesh Raja Mulakala holds an MBA from Case Western Reserve University, U.S.A. He is the Managing Director and Promoter of the Company and has more than 15 years of experience in setting up and managing businesses in the manufacturing and research & development sectors. He has been associated with the Company since its incorporation and has played a key role in its strategic leadership, innovation and operational management.</td></tr>
<tr><td>Past remuneration (per annum)</td><td colspan="4">Remuneration proposed/approved under previous appointment – Rs. 30.00 Lakhs p.a. (Rs. 2.50 Lakhs per month)</td></tr>
</table>

Job profile and suitability	As Managing Director, Mr. Dopesh Raja Mulakala is responsible for the overall management, strategic direction, business development and operations of the Company, subject to the superintendence, control and direction of the Board of Directors. Considering his qualifications, experience of more than 15 years in manufacturing and research & development businesses, knowledge of the Company's operations and his association with the Company since incorporation, the Board considers him suitable for continuing as Managing Director.
Recognition and Awards	Nil
Remuneration proposed	Rs. 2,50,000/- per month, together with such perquisites, benefits and other terms and conditions as approved by the Board and Members, subject to the provisions of Sections 196, 197, 198 and Schedule V to the Companies Act, 2013.
Comparative remuneration profile with respect to industry, size of the Company, profile of the position and person.	Taking into consideration the size and nature of operations of the Company, the responsibilities entrusted to the Managing Director, his qualifications, experience and the prevailing remuneration levels for comparable managerial positions in the industry, the proposed remuneration is considered reasonable and commensurate with the responsibilities of the position and industry standards.
Pecuniary relationship directly or indirectly with the Company, or relationship with the managerial personnel if any	Apart from the remuneration proposed to be paid to him and his shareholding / promoter interest in the Company, Mr. Dopesh Raja Mulakala has no other pecuniary relationship with the Company. He is not related to any other Director or Key Managerial Personnel of the Company.
III. OTHER INFORMATION	
Reasons of loss or inadequacy of profits	The Company had incurred losses in the previous financial year primarily due to lower revenue from operations coupled with the existing operating and finance cost structure. During FY 2025-26, however, the Company recorded improvement in its operating performance and returned to profitability.
Steps taken or proposed to be taken for improvement	The Company continues to focus on strengthening its preclinical research and safety assessment services, increasing business opportunities, improving utilisation of its capabilities, enhancing operational efficiencies, exercising cost controls and expanding its customer base in domestic and international markets.
Expected increase in productivity and profits	The measures undertaken by the Company are expected to contribute towards improved utilisation of resources, growth in revenue, better operating efficiencies and sustainable profitability. However, the actual increase in productivity and profits will depend upon market conditions, customer demand, regulatory developments and other business factors.
IV. DISCLOSURES:	
Details of proposed Remuneration	The disclosures relating to the remuneration package, terms of appointment, background, experience and other relevant particulars of Mr. Dopesh Raja Mulakala (DIN: 01176660), Managing Director, are set out in the Resolution under Item No. 3 of the Notice, the Explanatory Statement pursuant to Section 102 of the Companies Act, 2013, and elsewhere in this Annual Report, as applicable.

Annexure-A

Details of Directors seeking re-appointment at the forthcoming Annual General Meeting [Pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard 2 on General Meetings]

Name of the Director	**Mr. Dopesh Raja Mulakala**	
DIN	01176660	
Designation and category of the Director	Managing Director	
Date of Birth /Age	May 26, 1984 / 42 years	
Date of first appointment	April 29, 2016	
Qualifications	MBA, Case Western Reserve University, U.S.A	
Terms and Conditions of re-appointment along with remuneration sought to be paid	Retires by rotation and being eligible, offers himself for re-appointment at this 10th AGM. Further, Board has proposed his re-appointment as Managing Director for a period of 3 years w.e.f. 18.04.2026 at a remuneration and on terms as mentioned in Notice of this 10th AGM, subject to necessary approvals.	
Remuneration last drawn	Remuneration of Rs. 2,50,000/- p.m. and other terms and conditions have been approved by the Board and shareholders, however, he has not drawn any remuneration in FY 2025-26.	
Brief Resume and experience	Mr. Dopesh Raja Mulakala holds an MBA from Case Western Reserve University, U.S.A. He is the Managing Director and Promoter of the company, with a strong background in setting up and managing businesses in the manufacturing and research & development sectors. He has played a key role in the company's growth through strategic leadership, innovation, and operational excellence, further strengthening his expertise in business management and global enterprise development. He has experience of more than 15 years in setting up and running companies in the areas of manufacturing, research & development and is one of the promoters of Sarvotham Group – Hyderabad, India.	
Expertise in specific functional areas	Setting up and running companies in the areas of manufacturing, research & development	
Relationships between Directors *inter-se*	Not related to any Director or KMP	
Names of listed entities in which the person also holds the directorship	Nil	
Listed entities from which the person has resigned in the past three years	Nil	
Chairman/Member of the Committees of the Board of Directors of the Companies	Vanta Bioscience Limited	Sarvotham Care Limited
Audit Committee	Member	-
Nomination & Remuneration Committee	-	Member
Stakeholder Relationship Committee	Member	-
Shareholding	8,58,000 Equity Shares (12.06% of the total shareholding) as at 31.03.2026 (Kindly refer the website of the Company for share holding pattern and details of shares held by him)	

In case of independent directors, the skills and capabilities required for the role and the manner in which the proposed person meets such requirements	NA -
Number of meetings attended in FY 2025-26	6 out of the 6 meetings held
List of the directorships held in other companies (excluding foreign companies and Vanta Bioscience Limited)	● Sarvotham Care Limited ● Sarvotham Remedies Limited ● Shree Cosmetics Limited ● Sarvotham Solutions Limited ● CEBIS India Limited;

BOARD'S REPORT

Dear Members,

Your Directors have pleasure in presenting herewith the 10th Annual Report on the business and operations of Vanta Bioscience Limited (the "Company") together with the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026.

OUR BUSINESS

Vanta Bioscience Limited (VBS) is a preclinical contract research organization, offering a host of preclinical safety assessment services for clientele from Pharmaceutical, Medical Devices, Nutraceuticals, Feed Additive, Biotech, Agrochemicals, Cosmetics, and Chemical industries. In addition, we also provide risk assessment services for evaluating the safety of the Active Pharmaceutical Ingredients (API), excipients, extractable and leachables including pharmaceutical impurities resulting due to manufacturing process or due to degradation of the product. VBS also provides expert services for determination of health-based exposure limits (e.g. permitted daily exposure (PDE) or allowable daily exposure (ADE) including occupational exposure limits (OEL) for pharmaceutical manufacturers.

FINANCIAL HIGHLIGHTS

The financial performance of the Company during the period ended March 31, 2026 has been as under:

(Rs. in Thousands, except EPS)

Particulars	STANDALONE BASIS		CONSOLIDATED BASIS	
Financial year ended	**FY 2025-26**	**FY 2024-25**	**FY 2025-26**	**FY 2024-25**
Revenue from Operations	18,163.64	11,274.22	18,163.64	11,274.22
Add: Other Income	1,594.87	391.75	1,594.87	391.75
Total Income	**19,758.51**	**11,665.97**	**19,758.51**	**11,665.97**
Less: Total Expenses	19,505.93	38,856.54	19,621.50	38,971.06
Profit /(Loss) Before Tax (PBT)	**252.58**	**(27,190.57)**	**137.01**	**(27,305.09)**
Current Tax	-	-	-	-
Deferred Tax	(945.53)	(596.49)	(945.53)	(596.49)
Profit /(Loss) after Tax (PAT)	1,198.11	(26,594.08)	1,082.55	(26,708.60)
Earnings Per Share (in Rs.)	0.17	(4.21)	0.15	(4.23)

There was no change in the nature of business of your Company during the year under review.

STATEMENT OF AFFAIRS

Standalone Performance:

During the year under review, the Company recorded revenue from operations of Rs. 18,163.64 thousand as against Rs. 11,274.22 thousand in the previous year. The Company earned a Profit Before Tax of Rs. 252.58 thousand and Profit After Tax of Rs. 1,198.11 thousand as compared to Loss Before Tax of Rs. 27,190.57 thousand and Loss After Tax of Rs. 26,594.08 thousand, respectively, in the previous financial year.

Consolidated Performance:

The Company has one wholly owned subsidiary, Vanta Clinical Research Limited ("VCRL"). On a consolidated basis, the Company recorded revenue from operations of Rs. 18,163.64 thousand during FY 2025-26 as against Rs. 11,274.22 thousand in the previous year. The consolidated Profit Before Tax stood at Rs. 137.01 thousand and Profit After Tax at Rs. 1,082.55 thousand, as compared to Loss Before Tax of Rs. 27,305.09 thousand and Loss After Tax of Rs. 26,708.60 thousand, respectively, in the previous financial year.

REVIEW OF OPERATIONS

During the year under review, the Company continued to carry on its business as a preclinical Contract Research Organization (CRO), providing preclinical safety assessment and related research services to clients across the pharmaceutical, medical devices, nutraceuticals, feed additives, biotechnology, agrochemicals, cosmetics and chemical industries. The Company continued to focus on strengthening its service capabilities and supporting its clients through its preclinical and related research activities.

DIVIDEND

Your Board of Directors has not recommended any dividend for the financial year under review.

TRANSFER TO RESERVES

No amount has been transferred to general reserves during the year under review. Reserves and Surplus are disclosed in the financial statements.

DEPOSITS

The Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Companies Act, 2013 read with the Companies (Acceptance of Deposits) Rules, 2014 during the year under review .

During the year under review, the Company has obtained unsecured loan from Mr. Dopesh Raja Mulakala, Managing Director (DIN 01176660) of the Company and the outstanding unsecured loan as at March 31, 2026 was Rs. 8,915.00 thousand, details of which are disclosed in the financial statements.

The Company has also availed unsecured loans/borrowings from other related parties/body corporates during the year in compliance with the provisions of the Companies Act. The relevant details are disclosed in the Notes to the Financial Statements.

SUBSIDIARIES AND ASSOCIATE COMPANIES

The Company has one Wholly Owned Subsidiary, Vanta Clinical Research Limited ("VCRL") as at March 31, 2026. The Company has no associate company or joint venture as at the close of the financial year, the details of which are as follows:

Vanta Clinical Research Limited ("VCRL")

VCRL is a Wholly Owned Subsidiary of Vanta Bioscience Limited incorporated on September 12, 2018 with the object of dealing in the business of Research & Development in the field of discovery and development of drugs, biologicals, vaccines, gene-based therapies in vitro, ex-vivo and in vivo techniques for screening and evaluation of drugs, dermaceuticals and cosmetics, clinical data management, statistical analysis, pharmacovigilance, medical writing, bio informatics, computer-aided drug designing, biotechnology, life sciences, diagnostic services and such other similar activities. As on the date of this report, VCRL has not yet commenced commercial operations.

The paid up capital of VCRL as on March 31, 2026 was Rs. 3,00,00,000/-. There were no operations during the year under review. The Company had incurred a total expenditure of Rs. 115.57 thousand and accordingly had a Loss after Tax Rs. 115.57 thousand.

VCRL is a wholly owned subsidiary of our Company and whose financial statements have been included in the Consolidated Financial Statements.

During the year under review, CEBIS India Limited allotted additional shares to other persons, pursuant to which the percentage shareholding of Vanta Clinical Research Limited ("VCRL") in CEBIS India Limited was reduced to 19.90% on 15.03.2025, while the number of shares held by VCRL remained unchanged. Consequently, VCRL ceased to exercise significant influence over CEBIS India Limited and, accordingly, CEBIS India Limited ceased to be an indirect associate of the Company. Therefore, CEBIS India Limited has not been considered as an associate in the Consolidated Financial Statements of the Company for the financial year ended March 31, 2026.

The statement containing the salient features of the financial statements of the Wholly Owned Subsidiary, its financial position and performance and its contribution to the overall performance of the Company, pursuant to Section 129(3) of the Companies Act, 2013 read with Rule 5 of the Companies (Accounts) Rules, 2014, is provided in the prescribed Form AOC-1, which is annexed to this Report as Annexure-I.

The Annual Report of the Company, containing the Standalone and Consolidated Financial Statements, is available on the website of the Company at www.vantabio.com. The audited financial statements of the subsidiary are also available on the website of the Company. The same shall also be made available to the Members upon request in accordance with the applicable provisions of the Companies Act, 2013.

As at March 31, 2026, the Company has one Wholly Owned Subsidiary, Vanta Clinical Research Limited, and no associate company or joint venture. During the year under review, CEBIS India Limited ceased to be an associate of Vanta Clinical Research Limited and consequently ceased to be an indirect associate of the Company. Except as stated above, no company became or ceased to be a subsidiary, associate or joint venture of the Company during the financial year ended March 31, 2026.

POLICY ON MATERIAL SUBSIDIARIES

The Policy on Material Subsidiaries as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as approved by the Board is uploaded on the website of the Company and the web link is https://www.vantabio.com/investor-relations/.

DIRECTORS AND KEY MANAGERIAL PERSONNEL

During the year under review, the following changes took place in the Key Managerial Personnel of the Company:

S.No.	Name of the Director	Particulars
1	Ms. Sangeetha Padam Choudhary (ACS A64824) Company Secretary & Compliance Officer	Resigned from the position of Company Secretary & Compliance Officer of the Company w.e.f. November 1, 2025.
2	Ms. Pooja Kothari (ACS 64463) Company Secretary & Compliance Officer	Appointed as Company Secretary & Compliance Officer of the Company w.e.f. January 30, 2026.

Retirement by Rotation

In accordance with the provisions of Section 152 of the Companies Act, 2013 and the Articles of Association of the Company, Mr. Dopesh Raja Mulakala (DIN: 01176660), Managing Director, retires by rotation at the ensuing 10th Annual General Meeting and, being eligible, offers himself for re-appointment.

There was no change in the composition of the Board of Directors during the year under review. Except as stated above, there were no other changes in the Key Managerial Personnel of the Company during the financial year ended March 31, 2026.

DECLARATION BY INDEPENDENT DIRECTORS AND STATEMENT ON COMPLIANCE OF CODE OF CONDUCT

The Company has received declarations from all the Independent Directors pursuant to Section 149(7) of the Companies Act, 2013, confirming that they meet the criteria of independence prescribed under Section 149(6) of the Companies Act, 2013.The Independent Directors have confirmed that they are not aware of any circumstance or situation which exists or may reasonably be anticipated that could impair or impact their ability to discharge their duties with objective and independent judgment and without any external influence.

They have also complied with the Code for Independent Directors prescribed under Schedule IV to the Act and confirmed their registration in the Independent Directors' Databank maintained by the Indian Institute of Corporate Affairs. They have complied with the applicable requirements relating to the online proficiency self-assessment test conducted by the Indian Institute of Corporate Affairs, wherever applicable. In the opinion of the Board, all the Independent Directors possess the requisite integrity, expertise, experience and proficiency necessary for effectively discharging their duties except as mentioned below. The Board is satisfied that they are independent of the management and that there was no change in the circumstances affecting their status as Independent Directors during the year under review.

During FY 2025–26, the Independent Directors held a separate meeting without the presence of the Non-Independent Directors and members of the management. At the meeting, they reviewed:

i) the performance of the Non-Independent Directors and the Board as a whole;

ii) the performance of the Chairperson of the Company, taking into account the views of the Executive and Non-Executive Directors; and

iii) the quality, quantity and timeliness of the flow of information between the management and the Board necessary for the Board to effectively and reasonably perform its duties.

All the Independent Directors were present at the meeting.

Except Mr. Yogeswara Rao Danda (DIN: 00694803), all the Independent Directors have either passed the online proficiency self-assessment test or are exempt from appearing for the test. Mr. Yogeswara Rao Danda (DIN: 00694803), has not completed the online proficiency self-assessment test and shall comply with the applicable requirements in due course.

MEETINGS OF THE BOARD AND COMMITTEES

The Board of Directors meets at regular intervals to consider and review the business operations, financial performance, policies, strategies and other matters concerning the affairs of the Company. The intervening gap between meetings of the Board was within the period prescribed under Section 173 of the Companies Act, 2013 and the applicable Secretarial Standards.

During the financial year 2025-26, six (6) meetings of the Board of Directors were held on 06.05.2025, 01.08.2025, 06.09.2025, 01.11.2025, 14.11.2025 and 30.01.2026. All the Directors attended all the Board Meetings held during the year.

During the year under review:

i) Two (2) Audit Committee meetings was held on 01.08.2025 and 14.11.2025.

ii) One (1) Nomination & Remuneration Committee meeting was held on 30.01.2026

iii) One (1) Stakeholders Relationship Committee meeting was held on 06.05.2025.

The Board and committee meetings of the Company were held in compliance with all the applicable provisions of the Companies Act, 2013 and the Secretarial Standard-1 (SS-1) on Meetings of the Board of Directors issued by the Institute of Company Secretaries of India.

The 9th Annual General Meeting of the Company was held on 30.09.2025.

COMPOSITION OF BOARD COMMITTEES

The Company has constituted the committees of the Board in accordance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable. The composition of the committees as on the date of this Report is set out below:

AUDIT COMMITTEE

The Company has a duly constituted Audit Committee in accordance with Section 177 of the Companies Act, 2013 and other applicable provisions. The Committee comprises of the following members:

Name of Director	Designation	Category
Dr. Padmanabhuni Venkata Appaji	Chairman	Non- Executive Independent Director
Dr.Yogeswara Rao Danda	Member	Non- Executive Independent Director
Mr. Dopesh Raja Mulakala	Member	Managing Director - Executive

The Board of Directors of the Company has accepted all the recommendations given by the Audit Committee during the year under review.

Secretary to the Committee: The Company Secretary of the Company shall act as the Secretary to the Committee.

NOMINATION AND REMUNERATION COMMITTEE

The Committee comprises of the following members:

Name of Director	Designation	Category
Dr. Padmanabhuni Venkata Appaji	Chairman	Non- Executive Independent Director
Dr.Yogeswara Rao Danda	Member	Non- Executive Independent Director
Mr. Dopesh Raja Mulakala	Member	Managing Director - Executive

The Nomination and Remuneration Committee is constituted and functions in accordance with Section 178 of the Companies Act, 2013.

Secretary to the Committee: The Company Secretary of the Company shall act as the Secretary to the Committee.

STAKEHOLDERS' RELATIONSHIP COMMITTEE

The Committee comprises of the following members:

Name of Director	Designation	Category
Dr. Padmanabhuni Venkata Appaji	Chairman	Non- Executive Independent Director
Dr.Yogeswara Rao Danda	Member	Non- Executive Independent Director
Mr. Dopesh Raja Mulakala	Member	Managing Director - Executive

The Stakeholders' Relationship Committee is constituted and functions in accordance with Section 178 of the Companies Act, 2013. The Committee reviews and monitors the redressal of grievances of the security holders of the Company. No investor complaints were pending for resolution as at March 31, 2026.

Secretary to the Committee: The Company Secretary of the Company shall act as the **Secretary to the Committee**.

All the Committees operate in accordance with their respective terms of reference, the applicable provisions of the Companies Act, 2013, the rules made thereunder and the SEBI Listing Regulations, to the extent applicable.

BOARD EVALUATION, NOMINATION AND REMUNERATION POLICY

Pursuant to the provisions of Sections 134(3)(p), 149(8) and 178 of the Companies Act, 2013 read with Schedule IV thereto, and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable, the Company has established a framework for the annual evaluation of the performance of the Board, its Committees and individual Directors.

During the year under review, the annual performance evaluation process was carried out internally in accordance with the criteria and framework approved by the Nomination and Remuneration Committee and adopted by the Board. The evaluation covered:

- the performance of the Board as a whole;
- the performance of the Committees of the Board;
- the performance of individual Directors, including Independent Directors;
- the performance of the Chairperson of the Company; and
- the effectiveness of the Board's overall functioning and governance processes.

The performance of the Board was evaluated, inter alia, on the basis of its composition and diversity, qualifications and experience of its members, understanding of the Company's business, effectiveness of Board processes, quality of discussions, strategic guidance, risk oversight, succession planning, corporate governance practices and the adequacy and timeliness of information placed before the Board.

The performance of the Board Committees was evaluated on the basis of their composition, fulfilment of their respective terms of reference, effectiveness of discussions and deliberations, quality of recommendations made to the Board, frequency of meetings and the Committee's overall contribution to the functioning of the Board.

The evaluation of individual Directors was based, inter alia, on their attendance and preparedness for meetings, knowledge and understanding of the Company's business, active and constructive participation in deliberations, contribution to strategy and decision-making, exercise of independent judgement, adherence to ethical standards and the Code of Conduct, and discharge of their duties and responsibilities.

At their separate meeting held during the year, the Independent Directors, without the presence of Non-Independent Directors and members of the management, reviewed:

1. the performance of the Non-Independent Directors;
2. the performance of the Board as a whole;
3. the performance of the Chairperson of the Company, taking into account the views of the Executive and Non-Executive Directors; and
4. the quality, quantity and timeliness of the flow of information between the management and the Board which is necessary for the Board to effectively and reasonably perform its duties.

The performance evaluation of the Independent Directors was carried out by the entire Board, excluding the Independent Director being evaluated. In evaluating the Independent Directors, due consideration was given to their independence, objectivity, professional expertise, impartial judgement and contribution to Board and Committee deliberations.

The Directors expressed their satisfaction with the evaluation process and the overall functioning of the Board and its Committees.

STATUTORY AUDITORS

M/s. Mathesh & Ramana, Chartered Accountants (Firm Registration No. 002020S) were re-appointed as the statutory auditors of the Company by the members at the 7th Annual General Meeting held on 30.09.2023, for a second term of five (5) consecutive years, i.e. commencing from the conclusion of the 7th Annual General Meeting until the conclusion of the 12th Annual General Meeting of the Company. Their appointment is in accordance with the provisions of Sections 139 and 141 of the Companies Act, 2013 and the rules made thereunder. Accordingly, the said auditors have carried out the statutory audit for financial year 2025-26.

AUDITORS' REPORT

The Statutory Auditors' Reports on the Standalone and Consolidated Financial Statements of the Company for the financial year ended March 31, 2026 do not contain any qualification, reservation, adverse remark or disclaimer and the audit opinions are unmodified except that there are certain statutory amounts payable which are due for more than 6 months. The Statutory Auditors have further drawn attention by way of Emphasis of Matter to the non-provision for gratuity in the Standalone Financial Statements and, in the Consolidated Financial Statements, to the non-commencement of operations by the subsidiary and non-provision for gratuity by the Holding Company and its subsidiary. The Auditors have specifically stated that their opinions are not modified in respect of certain matters mentioned above.

BOARDS' RESPONSE

Certain observations relating to statutory dues and other matters have arisen primarily due to the liquidity and operational constraints faced by the Company. The Management is taking necessary steps to improve the financial and operational position of the Company and to strengthen its compliance processes. The Management shall endeavour to ensure timely payment and regularisation of statutory dues and other outstanding liabilities and shall take appropriate steps to address the other observations made by the Statutory Auditors.

With respect to the non-provision for gratuity, the Management shall take necessary steps to evaluate and appropriately recognise the gratuity liability in accordance with the applicable accounting standards and statutory requirements. Further, with respect to the subsidiary which has not yet commenced operations, the Management is evaluating appropriate measures for commencement of its operations and improvement of its financial position. The Board shall continue to monitor the developments in this regard.

Further, Notes to Accounts and Auditors remarks in their report are self-explanatory and do not call for any further comments. Further details are also disclosed at various places in this Boards' Report and in the financial statements.

There were no frauds reported by the Statutory Auditors of the Company during the year under review.

INTERNAL AUDITORS

Pursuant to the provisions of Section 138 of the Companies Act, 2013 read with the Companies (Accounts) Rules, 2014, the Board had appointed M/s. V. Ramachandra Rao, Chartered Accountants (Membership No. 203292) as the Internal Auditor of the Company for a period of two financial years, i.e., FY 2024-25 and FY 2025-26.

Accordingly, the Internal Auditor carried out the internal audit of the Company for FY 2025-26 and reported its findings to the Audit Committee. No material observations or remarks were reported by the Internal Auditor during the year under review.

SECRETARIAL AUDIT REPORT

Pursuant to the provisions of Section 204 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, Ms. Putcha Sarada, Practicing Company Secretary (Membership No. A21717, Certificate of Practice No. 8735), was appointed to conduct the Secretarial Audit of the Company for the financial year 2025-26.

The Secretarial Audit Report for the financial year ended March 31, 2026, in Form MR-3, forms part of this Board's Report as Annexure-II.

The Company acknowledges the observations and submits that the lapses were largely attributable to the cascading impact of the CIRP proceedings, financial constraints and liquidity issues faced by the Company. Further, several experienced employees handling compliance and related matters had left the organisation during the period, resulting in operational challenges. The Company is presently recovering from the aforesaid circumstances and has strengthened its internal structure and is in the process of inducting suitable personnel. Certain compliances have already been rectified and the Company is taking necessary steps to regularise the remaining pending compliances at the earliest. The Company has put in place appropriate systems and processes to ensure that such lapses do not recur and that all applicable compliances are adhered to in a timely manner going forward.

ISSUE AND ALLOTMENT OF SECURITIES / CHANGES IN SHARE CAPITAL

The Authorized Share Capital of the Company is Rs. 7,50,00,000/- (Rupees Seven Crore and Fifty Lakhs only), divided into 75,00,000 (Seventy-Five Lakh) Equity Shares of Rs. 10/- each.

As at the beginning of the financial year, the Issued, Subscribed and Paid-up Share Capital of the Company stood at Rs. 6,31,20,000/- (Rupees Six Crore Thirty-One Lakh and Twenty Thousand only) comprising 63,12,000 (Sixty-Three Lakh Twelve Thousand) Equity Shares of Rs. 10/- each.

During the year under review, pursuant to the approval of the Members at their meeting held on 04.01.2025 and in accordance with the applicable provisions of the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 and other applicable laws, the Board of Directors at its meeting held on 06.05.2025 allotted 8,00,000 (Eight Lakh) Equity Shares of face value Rs. 10/- each at a premium of Rs. 40/- each, on a preferential basis, upon conversion of unsecured loans, to promoters, Mr. Dopesh Raja Mulakala (4,00,000 Equity Shares) and Mr. S. Chandra Sekhar Rao (4,00,000 Equity Shares).

Consequent to the aforesaid allotment, the Issued, Subscribed and Paid-up Equity Share Capital of the Company increased to Rs. 7,11,20,000/- (Rupees Seven Crore Eleven Lakh Twenty Thousand only) comprising 71,12,000 (Seventy-One Lakh Twelve Thousand) Equity Shares of Rs. 10/- each as at March 31, 2026. The equity shares so allotted rank pari passu in all respects with the existing Equity Shares of the Company.

CORPORATE SOCIAL RESPONSIBILITY

The provisions of Section 135 of the Companies Act, 2013 in connection with corporate social responsibility are not applicable to the Company.

VIGIL MECHANISM

Pursuant to the provisions of Section 177(9) & (10) of the Companies Act, 2013 and the applicable SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a Vigil Mechanism or Whistle-Blower Policy for directors, employees and other stakeholders to report genuine concerns has been established. The same is also uploaded on the website of the Company – www.vantabio.com

RISK MANAGEMENT POLICY

The Risk Management is overseen by the Audit Committee of the Company on a continuous basis. The Committee oversees Company's process and policies for determining risk tolerance and review management's measurement and comparison of overall risk tolerance to established levels. There are no material risks which threaten the very existence of the company.

INTERNAL FINANCIAL CONTROLS

Your Company has an adequate system of internal financial controls with reference to financial statements, including but not limited to safeguard and protection of assets from loss, their unauthorized use or disposition. All the transactions were properly authorized, recorded and reported to the Management. Your Company is following all the applicable Accounting Standards for properly maintaining the books of accounts and reporting in the financial statements. During the year under review, your Company continues to ensure proper and adequate systems and procedures commensurate with its size and nature of its business.

SECRETARIAL STANDARDS

The Directors state that applicable secretarial standards i.e., Secretarial Standard-1 and Secretarial Standard-2 relating to 'Meeting of the Board of Directors' and 'General Meetings' respectively, have been duly complied by the Company.

DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(3)(c) read with Section 134(5) of the Companies Act, 2013, the Directors, to the best of their knowledge and ability, confirm that:

i. In the preparation of the Annual Accounts for the financial year ended March 31, 2026, the applicable Accounting Standards have been followed and that no material departures are made from the same;

ii. The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company as at March 31, 2026 and of the profits of the company for the year ended on that date;

iii. Proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

iv. The annual accounts have been prepared on a going concern basis.

v. The Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and

vi. The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE OUTGO

Information required under section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is enclosed herewith as **Annexure-III**.

ANNUAL RETURN

Form MGT 7 - the annual return of the Company for FY 2025-26 shall also be uploaded on the website of the Company. The link of the same is https://www.vantabio.com/investor-relations/

PARTICULARS OF EMPLOYEES

The information required pursuant to Section 197(12) read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and as amended in respect of our employees, is attached herewith and marked as **Annexure –IV**. Your Company hereby affirms that the remuneration paid is as per the Remuneration Policy for Directors, Key Managerial Personnel and other Employees.

Further, Company does not have any employee whose remuneration falls within the purview of the limits prescribed under the provisions of Section 197 of the Companies Act, 2013, read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and as amended i.e. Rs.8.5 lakhs per month or Rs.1.02 Crores per annum.

MANAGEMENT DISCUSSION AND ANALYSIS

The Management Discussion and Analysis Report as required under Schedule V of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is enclosed as Annexure - V to this report.

CORPORATE GOVERNANCE

The Company is committed to maintaining high standards of corporate governance, integrity, transparency and accountability and seeks to enhance long-term stakeholder value while protecting the interests of all stakeholders, including minority shareholders. The Equity Shares of the Company are listed on the SME Platform of BSE Limited. Accordingly, pursuant to

Regulation 15(2)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, compliance with the corporate governance provisions specified in Regulations 17 to 27 and the related disclosures prescribed under Schedule V of the Listing Regulations is not mandatory for the Company. Notwithstanding the aforesaid exemption, the Company continues to comply with the applicable provisions of the Companies Act, 2013 and follows sound corporate governance practices, wherever considered appropriate.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The loans, investment and guarantees provided by the Company during the year has not exceeded the limit approved by the shareholders in accordance with Section 186 of the Companies Act, 2013. The Company is in compliance with the provisions of Section 186 of the Companies Act.

The Company has investments in its Wholly Owned Subsidiary – Vanta Clinical Research Limited. Details of loans, investments and guarantees as applicable are disclosed in Note 12 of the financial statements and also at other places in the financial statements.

LISTING & TRADING

The Equity Shares of your Company are listed and traded on the SME Platform of BSE Limited under Scrip Code 540729. The annual listing fees for the financial year 2025-26 have been duly paid.

DEMATERIALIZATION OF SHARES

The entire paid-up Equity Share Capital of your Company is held in dematerialized form as on March 31, 2026. The International Securities Identification Number (ISIN) allotted to the Equity Shares of the Company is INE695X01011.

MAINTENANCE OF COST RECORDS

The provisions of cost records as specified by the Central Government under sub-section (1) of Section 148 of the Companies Act, 2013 are not applicable to the Company.

RELATED PARTY TRANSACTIONS

During the year under review, the Company entered into transactions with related parties in the ordinary course of business and for business requirements, administrative convenience and in the best interest of the Companies. There were no materially significant related party transactions with the Company's Promoters, Directors, Management or their relatives, which could have had a potential conflict with the interests of the Company. All related party transactions entered by the Company under Section 188 of the Companies Act, 2013 are at arm's length and in the ordinary course of business and there were no material related party transactions under Section 188 of the Companies Act, 2013.

The Company has entered into any transactions with person or entity belonging to the promoter/promoter group which holds 10% or more shareholding in our Company. Details of all related party transactions are disclosed in the Notes of the financial statements. The Policy on Related Party Transactions is available on the Company's website https://www.vantabio.com/investor-relations/.

RECLASSIFICATION OF PROMOTERS

The Company received requests from Dr. Vyasmurti Madhavrao Shingatgeri and Mr. Pradeep Chowdary Veeramachineni, forming part of the Promoter Group, for reclassification of their status from “Promoter” to “Public” category in accordance with Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board, at its meeting held on July 19, 2024, approved the reclassification requests and submitted the application to BSE Limited. The said application has been rejected by BSE vide their letter dated 13.06.2025 as the Company had not obtained shareholders resolution for the same.

GENERAL

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

1. Issue of equity shares with differential rights as to dividend, voting or otherwise.
2. Issue of shares (including sweat equity shares) to employees of the Company under any scheme.
3. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future.
4. No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year and date of report.
5. There was no instance of one-time settlement with any Bank or financial institution.
6. There are no shares lying in Demat suspense account or unclaimed suspense account.
7. Any other/additional disclosures pursuant to Section 134 and other applicable provisions, if any of the Act and rules framed thereunder and as under SEBI Regulations or under any other applicable statutory provisions, to the extent not specifically set out in this Board's Report may not be applicable to the Company or have been appropriately disclosed elsewhere in this Annual Report
8. There are no binding agreements signed by the Company. Accordingly, no disclosure is required to be made in this regard.

The Company being listed on SME Exchange. Para C, D and E of Schedule V of SEBI (LODR) Regulations, 2015 in connection with disclosures in the annual report are not applicable to the Company.

INSIDER TRADING REGULATIONS

Based on the requirements under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the code of conduct for prevention of insider trading and the Code for Corporate Disclosures ("Code"), as approved by the Board from time to time, are in force by the Company. The objective of this Code is to protect the interest of shareholders at large, to prevent misuse of any price sensitive information and to prevent any insider trading activity by dealing in shares of the Company by its Directors, designated employees and other employees.

The Company also adopts the concept of Trading Window Closure, to prevent its Directors, Officers, designated employees and other employees from trading in the securities of Vanta Bioscience Limited at the time when there is unpublished price sensitive information.

OBLIGATION OF THE COMPANY UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

Your Company strongly supports the rights of all our employees to work in harassment – free environment. We have adopted a Policy on Prevention, Prohibition and Redressal of Sexual Harassment at workplace as per the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 ("POSH Act") and the Rules made thereunder. The policy aims to provide protection to Employees at the workplace and prevent and redress complaints of sexual harassment and for matters connected or incidental thereto, with the objective of providing a safe working environment, where Employees feel secure.

Further, Company has in place a Committee under the name and style "Internal Complaints Committee" in compliance with the POSH Act which looks into various matters concerning harassment, if any, against women at workplace, addresses concerns and complaints of sexual harassment and recommends appropriate action. This Committee was constituted to specifically provide a safe, secure and enabling environment, free from sexual harassment to every woman.

Your Company further confirms that during the year under review, there were no cases filed pursuant to the said Act. Following are the details of complaints:

Sl. No.	Particulars	Details
1	Number of complaints of sexual harassment received during the financial year 2024-25	Nil
2	Number of complaints disposed off during the financial year	Nil
3	Number of cases pending for more than ninety days	Nil

COMPLIANCES OF MATERNITY BENEFIT ACT,1961

The Company confirms that it has complied with the provisions of the Maternity Benefit Act, 1961, including granting maternity leave, nursing breaks, and protection against dismissal during maternity leave, as applicable to eligible employees during the financial year, if any.

ACKNOWLEDGEMENTS

Your Directors place on record their appreciation of the continued patronage extended to the Company by bankers, dealers, customers, suppliers, employees and shareholders. The trust reposed in your Company by its esteemed customers helped stabilized growth during the year under review.

Your Company also acknowledges the support and guidance received from its Bankers, other government agencies during the year under review and looks forward to continuing support.

For and on behalf of the Board
Vanta Bioscience Limited

Sd/-
DOPESH RAJA MULAKALA
Managing Director
DIN: 01176660

Sd/-
PADMANABHUNI VENKATA APPAJI
Director
DIN: 02614167

Place: Hyderabad
Date: 05.09.2026

ANNEXURE-I

FORM AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries / associate companies / joint ventures.

PART "A" – Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs. In thousands)

Sl.No.	Particulars	Details
1.	Name of the subsidiary	Vanta Clinical Research Limited
2.	The date since when subsidiary was acquired	September 12, 2018
3.	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Not Applicable – Same as Holding Company
4	Reporting currency and Exchange rate as on the last date of the relevant Financial year in the case of foreign subsidiaries	-
5.	Share capital	30,000.00
6.	Reserves & surplus	(775.67)
7.	Total assets	39,383.44
8.	Total Liabilities	10,159.11
9.	Investments	30,000.00
10.	Turnover	-
11.	Profit before taxation	(115.57)
12.	Provision for taxation	-
13.	Profit after taxation	(115.57)
14.	Proposed Dividend	-
15.	Extent of shareholding (In percentage)	100.00%

Notes:

1. **Name of subsidiary yet to commence operations: Vanta Clinical Research Limited**, incorporated on 12.09.2018, had not commenced commercial operations as at March 31, 2026.
2. **Names of subsidiaries which have been liquidated or sold during the year**: Nil
3. **Subsidiaries liquidated during the year**: Nil.

For and on behalf of the Board of Directors
Vanta Bioscience Limited

For **Mathesh & Ramana**
Chartered Accountants

Sd/-
B. V. Ramana Reddy
M. No. 026967
Partner

Sd/-
Dopesh Raja Mulakala
Managing Director
DIN: 01176660

Sd/-
Padmanabhuni Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date: 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
CFO

Part "B": Associates and Joint Ventures
Statement pursuant to Section 129(3) of the Companies Act, 2013 relating to Associate Companies and Joint Ventures

Particulars	Details
Name of the Associate Company or Joint Venture	Not Applicable
Latest audited Balance Sheet date	Not Applicable
Date on which the Associate Company or Joint Venture was associated or acquired	Not Applicable
Shares of Associate Company or Joint Venture held by the Company at the year-end – Number	Nil
Amount of investment in Associate Company or Joint Venture	Nil
Extend of Holding	Nil
Description of how there is significant influence	Not Applicable
Reason why the Associate Company or Joint Venture is not consolidated	Not Applicable
Net worth attributable to the Company's shareholding as per the latest audited Balance Sheet	Nil
Profit/(Loss) for the year	Nil
Profit/(Loss) considered in consolidation	Nil
Profit/(Loss) not considered in consolidation	Nil

Notes:

1. The Company did not have any Associate Company or Joint Venture during the financial year ended March 31, 2026.
2. Names of Associate Companies or Joint Ventures which are yet to commence operations: Nil.
3. Names of Associate Companies or Joint Ventures which have been liquidated or sold during the year:

   CEBIS India Limited ceased to be an Associate Company of Vanta Clinical Research Limited, the Wholly Owned Subsidiary of the Company, during the financial year 2025-26 and consequently ceased to be an indirect Associate Company of Vanta Bioscience Limited. Accordingly, CEBIS India Limited is not considered as an Associate Company of the Company as at March 31, 2026 and has not been considered as an associate in the Consolidated Financial Statements for the year ended March 31, 2026.

For and on behalf of the Board of Directors
Vanta Bioscience Limited

For **Mathesh & Ramana**
Chartered Accountants

Sd/-
B. V. Ramana Reddy
M. No. 026967
Partner

Sd/-
Dopesh Raja Mulakala
Managing Director
DIN: 01176660

Sd/-
Padmanabhuni Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date: 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
CFO

Annexure - II

Form No. MR-3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED March 31, 2026

(Pursuant to Section 204 (1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014)

To,

The Members,

VANTA BIOSCIENCE LIMITED

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Vanta Bioscience Limited bearing CIN: L74999TG2016PLC109280 (hereinafter called the “Company”). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing my opinion thereon.

Based on my verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorised representatives during the conduct of secretarial audit and as per the explanations given to me and the representations made by the Management, I hereby report that in my opinion, the Company has, during the audit period covering the financial year ended on March 31, 2026 generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

I have examined the books, papers, minute books, forms and returns filed and other records made available to me and maintained by the Company for the financial year ended on March 31, 2026 according to the applicable provisions of:

i. The Companies Act, 1956 and the Companies Act, 2013 ('the Act') and the rules made there under;

ii. The Securities Contract (Regulation) Act, 1956 ('SCRA') and the rules made there under;

iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;

iv. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings - Not Applicable during the audit period;

v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

   a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;

   b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;

   c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

   d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 - Not Applicable during the audit period;

   e) Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 - Not Applicable during the audit period;

   f) Securities and Exchange Board of India (Issue and Listing of Non- Convertible Securities) Regulations, 2021 - Not Applicable during the audit period;

   g) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

   h) Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 - Not Applicable during the audit period;

   i) Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993.

vi. Other Laws specifically applicable to the Company:

   a. Pharmacy Act, 1948

   b. Bio-Medical Waste Management Rules, 2016

   c. Legal Metrology Act, 2009;

   d. Prevention of Cruelty to Animals Act, 1960 and the Breeding of and Experiments on Animals (Control and Supervision) Rules, 1998

e. Guidelines for care and use of animals in scientific research
f. Good Laboratory Practices
g. Water (Prevention and Control of Pollution) Act, 1974
h. Water (Prevention and Control of Pollution) Cess Act, 1977
i. Air (Prevention and Control of Pollution) Act, 1981
j. Environment (Protection) Act, 1986
k. The Public Liability Insurance Act, 1991
l. The Biodiversity Act, 2002
m. Hazardous Wastes (Management and Handling) Rules, 1989
n. Hazardous Wastes (Management, Handling and Transboundary Movement) Rules, 2008
o. Manufacture, Storage and Import of Hazardous Chemicals Rules, 1989;
p. Explosives Act, 1884.
q. Explosives Rules, 2008.

I have also examined compliance with the Secretarial Standards issued by the Institute of Company Secretaries of India and the Listing Regulations as applicable to the Company.

The compliance of the above laws is based on the Compliance Certificate issued by the Company and submitted to the Board of the Company. During the Audit Period under review and as per the explanation and clarifications given to me and the representations made by the Management, the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines, etc. mentioned above except as stated below:

1. *The Company has not filed Form AOC 4, MGT 7 for FY 2024-25 and other forms as applicable during the year under review.*
2. *The Company had delayed in submission of financial results under Regulation 33, Annual Report under Regulation 34 and shareholding pattern under Regulation 31 of the SEBI (LODR) Regulations, 2015 for the period ended 31.03.2025. BSE levied penalties in respect of such delays as per applicable SEBI Master Circulars. The Company has subsequently complied with the aforesaid requirements and paid the applicable penalties, thereby regularizing the same.*

I further report that, during the year under review:

a) The Company had filed certain forms after the due date upon payment of additional fees.

b) Mr. Yogeswara Rao Danda, Independent Director is yet to write the online proficiency exam as required for Independent Directors under the Companies Act.

c) Dr. Vyasmurti Madhavrao Shingatgeri and Mr. Pradeep Chowdary Veeramachineni, Promoters vide their letters dated 19.07.2024 have requested for reclassification from Promoter to Public category in terms of Regulation 31A of SEBI (LODR) Regulations. The Board of the Company in their meeting held on 19.07.2024 has approved the same and has filed necessary application with BSE Ltd for their approval. The said application has been rejected by BSE vide letter dated 13.06.2025 stating that the said reclassification requires the approval of the shareholders.

d) The Company has delayed in depositing certain undisputed statutory dues i.e. provident fund, employees' state insurance, professional tax and TDS. The Company has outstanding statutory dues of provident fund, professional tax and TDS which were outstanding at the year-end for a period of more than six months from the date they became payable.

e) Vanta Clinical Research Limited, the WOS of the Company had not yet started its operations and has incurred cash losses during the year and in the immediately preceding financial year. however, the financials of the Company have been prepared on going concern basis;

f) The Company has created provision for Gratuity but the actuarial valuation based on which such provision is to be created is not found on record in case of holding and subsidiary company.

g) The company has granted loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment,

h) The compliance by the Company of applicable financial laws, like direct and indirect tax laws, have not been reviewed in this Audit since the same has been subject to review by statutory financial audit and other designated professionals;

I further report that:

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non -Executive Directors and Independent Directors. The composition of the Board of Directors are in compliance with the provisions of the Act. There were no changes in the composition of the Board during the period under review.

Adequate notice was given to all Directors at least seven days in advance to schedule the Board Meetings, agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting. Whenever required, the Board has also met with a notice shorter than seven days.

Decisions at the Board Meetings, as represented by the management, were taken by majority and recorded as part of the minutes.

As per the explanations given to me and the representations made by the Management and relied upon by me, I further report that there were lapses in compliance with certain provisions of the Companies Act and SEBI (LODR) Regulations. The systems and processes in the Company needs improvement to commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

Sd/-
Sarada Putcha
Practicing Company Secretary
M.No. A21717
C.P. No.: 8735
UDIN: A021717H001391811

September 05, 2026
Place: Hyderabad

This Report is to be read with my letter of even date which is annexed as Annexure A and forms an integral part of this report.

Encl:

Annexure-A

Annexure - A

To,

The Members,
VANTA BIOSCIENCE LIMITED

My report of even date is to be read along with this letter

MANAGEMENT'S RESPONSIBILITY

1. Maintenance of Secretarial record is the responsibility of the management of the Company. My responsibility is to express an opinion on these secretarial records, standards and procedures followed by the Company with respect to secretarial compliances based on my audit.

AUDITOR'S RESPONSIBILITY

2. I have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the process and practices, I followed provide a reasonable basis for my opinion.

3. Where ever required, I have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.

4. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedure on test basis.

DISCLAIMER

5. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

6. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

Sd/-
Sarada Putcha
Practicing Company Secretary
M.No. A21717
C.P. No.: 8735

September 05, 2026
Place: Hyderabad

Annexure – III

STATEMENT PURSUANT TO SECTION 134(3)(M) OF THE COMPANIES ACT, 2013 READ WITH RULE 8 OF THE COMPANIES (ACCOUNTS) RULES, 2014

(A) Conservation of energy-

(i) **the steps taken or impact on conservation of energy**:

The Company continues to take appropriate measures for conservation and efficient utilisation of energy at its Research Centre/Laboratory and other facilities. Energy consumption is monitored and efforts are made to avoid unnecessary usage and optimise consumption in the normal course of operations.

(ii) **the steps taken by the company for utilizing alternate sources of energy:** Nil

(iii) **the capital investment on energy conservation equipments:** Nil

(B) Technology absorption-

(i) **the efforts made towards technology absorption:**

The Company continues to adopt and utilise appropriate technologies, laboratory techniques and processes in its preclinical research and testing activities to improve operational efficiency and quality of services.

(ii) **the benefits derived like product improvement, cost reduction, product development or import substitution:**

The adoption of appropriate technologies and laboratory processes has contributed to improved quality and efficiency of the Company's preclinical research and testing services.

(iii) **in case of imported technology (imported during the last three years reckoned from the beginning of the financial year)-**

(a) the details of technology imported: Nil

(b) the year of import: Nil

(c) whether the technology been fully absorbed: Nil

(d) if not fully absorbed, areas where absorption has not taken place, and the reasons thereof: Nil

(iv) **the expenditure incurred on Research and Development:** Rs. 68,630.73 thousand was spent towards Research & Development by the Company during the year under review. Refer financial statements for further details.

(C) Foreign exchange earnings and Outgo- (Rs. In Thousands)

The Foreign Exchange earned in terms of actual inflows during the year: 2,305.68

The Foreign Exchange outgo during the year in terms of actual outflows: Nil

During the year, there was a foreign exchange gain of Rs. 1584.91 to the Company.

For and on behalf of the Board

Sd/-	Sd/-
Dopesh Raja Mulakala	**Padmanabhuni Venkata Appaji**
Managing Director	Director
DIN: 01176660	DIN: 02614167

Place: Hyderabad
Date: 05.09.2026

Annexure - IV

Information pursuant to Section 197 read with Rule 5 (1) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and as amended in respect of our employees

1. The ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2025-26 and the percentage increase in remuneration of each Director / Key Managerial Personnel, as applicable, are as follows:

(Amount in Rs.)

Sl. No.	Name of Director / KMP and Designation	Financial Year 2025-26		
		Remuneration of Director / KMP (in Rs.)	% increase in Remuneration	Ratio of Remuneration of each Director to median remuneration of employees
1	Mr. Mulakala Dopesh Raja (Managing Director)	Nil	Nil	Nil
2	Dr. Padmanabhuni Venkata Appaji (Non-Executive & Independent Director)	Nil	Nil	Nil
3	Dr. Gonuguntla Kathyayani (Non-Executive& Independent Director)	Nil	Nil	Nil
4	Dr. Yogeswara Rao Danda (Non-Executive& Independent Director)	Nil	Nil	Nil
5	Mr. Dokka Venkata Sathya Murali (Chief Financial Officer)	4,42,790	(57.93%)	1.78:1
6	Ms. Sangeetha Padam Choudhary (Company Secretary & Compliance Officer)	3,00,000	Nil	1.21:1
7	Ms. Pooja Kothari (Company Secretary & Compliance Officer)	3,00,000	Nil	1.21:1

Note: Ms. Sangeetha Padam Choudhary resigned from the position of Company Secretary and Compliance Officer with effect from 01.11.2025. Ms. Pooja Kothari was appointed as Company Secretary and Compliance Officer with effect from 30.01.2026. Median remuneration of employees for FY 2025-26: Rs. 2,48,600.

2. **The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year;**

   During the financial year 2025-26, there was no increase in the remuneration of the Directors. The remuneration of Chief Financial Officer, decreased by 57.93% as compared to the previous financial year. Ms. Pooja Kothari was appointed as Company Secretary and Compliance Officer with effect from 30.01.2026; hence, the percentage increase in her remuneration is not applicable.

3. **The percentage increase in the median remuneration of employees in the financial year;**

   In the financial year, the median remuneration of employees decreased by 33.59% during FY 2025-26.

4. **Number of permanent employees on the rolls of Company as on March 31, 2026** – 38 Employees

5. **Average percentile increases already made in the salaries of the employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in managerial remuneration.**

   The average percentile increase in the salaries of employees other than managerial personnel was Nil during FY 2025-26. There was no increase in managerial remuneration during the year and no exceptional circumstances for increase in managerial remuneration.

6. **Affirmation that the remuneration is as per the Remuneration Policy of the Company:**

   It is hereby confirmed that the remuneration is as per the Remuneration Policy of the Company.

AnnexureIII

Statement of particulars of Employees Pursuant to section 197(12) of the Companies Act, 2013 read with Rule 5(2) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 Details of top 10 Employees (in terms of remuneration drawn) throughout the year/part of the year:

Sl. No.	Name	Age	Designation	Qualification	Remuneration (Rs. p.a.)	Nature of Employment	Experience (Years)	Date of Commence-ment of Employment	Previous Employment	No. of Equity Shares held	Relative of Director / Manager
1	Vadlamani Girish Shankar Sharma	53	sr.vice president & dy.tfm	Material Management, M.Sc.	36,93,527	Permanent	30	24.04.2017	Madhav Universityand Rattan Power Ltd.	None	No
2	Paramasivam Karthikeyan	53	tfm & head	MSC	23,09,421	Permanent	28	23.04.2025	Konark Research Foundation	None	No
3	Senguttuvan Dilli	58	DMLT	DMLT	8,58,746	Permanent	35	01.04.2017	Kemis PVT Ltd.; Kemis GS India PVT Ltd.	None	No
4	Chilam Srikanth	45	Deputy Manager – Accounts	B.Com	8,43,192	Permanent	23	01.03.2018	REINS SV Enterprises	None	No
5	Niranjan Mahadev	44	sr.research scntst-head-qa	MSC	7,44,711	Permanent	21	30.07.2025	-	None	No
6	Pankaj Kumar Mandal	43	Research Associate-II	B.A.	6,46,833	Permanent	20	30.08.2021	Raj Scientific Research & Development Organisation	None	No
7	Loganayagi Viswanatham	49	Research Scientist	M.Sc., M.Phil., Ph.D.	5,86,400	Permanent	25	16.11.2023	Madurai University and Pothigai Power Ltd.	None	No
8	M. Ravindran	31	Research Associate-II	B.Tech. Biotechnology	5,59,822	Permanent	8	15.04.2019	Micro Therapeutic Research Labs Pvt. Ltd.	None	No
9	Pannerselvam L	39	research scientist-I	DMLT, BBA	5,18,933	Permanent	15	01.04.2017	Kemin & SGS India Private Limited	None	No
10	Pushparaj K	41	sr.officer-technical	B TECH	4,88,815	Permanent	15	01.04.2017	-	None	No

Annexure - V

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

1. Industry Structure and developments

Vanta Bioscience Limited (“Vanta” or “the Company”) is an emerging full-service preclinical contract research organization (CRO), operating out of Chennai, India. The Company is established as a center of excellence in GLP-compliant toxicology and safety assessment services.

Industry Overview

India continues to be one of the largest and fastest-growing economies in the world. Among the key contributors to this growth are the Food & Agriculture and Pharmaceutical industries. The Food & Agri sector is one of the top three pillars driving the Indian economy and is poised for continued robust growth. The pharmaceutical industry, a vital segment of the Indian economy, is currently experiencing challenges such as increased global regulatory scrutiny and a slowdown in key markets, including the United States. Despite these headwinds, the Indian pharmaceutical sector remains resilient, with rising investments in R&D and a growing trend of outsourcing compliance-related testing services.

Growing awareness around food safety and quality, driven by the Food Safety and Standards Authority of India (FSSAI), along with an increasingly quality-conscious consumer base, is also driving demand for advanced testing services. These trends are opening significant opportunities in the food and pharmaceutical testing and research services space, spanning both routine and specialized studies. However, these opportunities are accompanied by several challenges, including rising competition from both domestic and international players, a shortage of skilled and trained professionals in specialized domains, and an uneven playing field in terms of service quality and the perceived value of such services by customers.

Globally, healthcare spending is at an all-time high, particularly due to the growing demand for innovative and accessible medications in emerging markets. Pharmaceutical companies are under constant pressure to accelerate the drug development cycle and maximize returns on investment. This has led to a shift toward specialty healthcare segments and cost-effective R&D solutions. Although India is not yet among the top destinations for outsourcing new R&D activities, its cost advantages and technical capabilities present a compelling value proposition for the global pharmaceutical industry. With continued improvements in infrastructure, quality standards, and regulatory compliance, India's position in the global clinical and preclinical research ecosystem is expected to strengthen in the years to come.

2. Opportunities and Threats / Risks and concerns

Opportunities:

Our Company has strategically expanded its footprint through exclusive tie-ups in the preclinical services sector in Greater China, along with non-exclusive agreements covering Latin America (LATAM) and Asia Pacific (APAC) for the Chemical and Agrochemical business. The recent enhancement of our GLP scope, especially in physicochemical and toxicological studies, is expected to generate new revenue streams in the upcoming quarters. Strengthened regulatory oversight by bodies like FSSAI on food safety and quality, alongside global emphasis on GLP, NABL, and MHRL compliance, further bolster market prospects.

The Indian pharmaceutical industry continues to maintain a strong position in the global pharmaceutical market, supported by its manufacturing capabilities, skilled scientific workforce, cost competitiveness and growing focus on research and innovation. The Indian pharmaceutical market is estimated at approximately US$60 billion (Rs. 5.30 lakh crore) in FY 2025-26 and is projected to reach approximately US$130 billion (Rs. 12.47 lakh crore) by 2030. India also continues to be a major global supplier of generic medicines and vaccines.

The continued expansion of the pharmaceutical and life sciences sectors, increasing expenditure on research and development, growing regulatory requirements and the increasing trend towards outsourcing specialised research, testing and development activities are expected to create opportunities for the Contract Research Organization (CRO) industry. For Vanta, these developments provide opportunities in preclinical research, toxicology, safety assessment, physicochemical studies and other specialised testing services.

Threats:

Our facilities are subject to client inspections and stringent quality audits, and any failure to meet contractual quality standards could lead to termination of contracts, adversely impacting business operations and financial performance. Significant disruptions in IT systems or breaches in data security pose risks to operational continuity. Foreign exchange fluctuations, political and economic uncertainties, and evolving laws and regulations in India including corporate and tax laws, also present ongoing risks.

Challenges, Risks, and Concerns:

Risks are inherent in any business, and the interplay between opportunities and challenges requires vigilant management. Our Company addresses these through a robust risk management framework encompassing identification, mitigation, and continuous monitoring of risks. We remain committed to maintaining a competitive edge by innovating new service offerings while upholding stringent quality standards, regulatory compliance, and exceptional customer service.

3. Segment Wise or Product Wise Performance

The Company is providing services of Testing and Contract Research in the fields of Clinical Research, Pre-Clinical Research, Biopharma services, Analytical Testing & Research and Environmental studies. Since the inherent nature of all these services are inter related and governed by similar set of risks and returns and operating in the same economic environment, segment reporting is not applicable. Accordingly, for reporting purposes, all these services are treated as single business and geographical segment. The said treatment is in accordance with Accounting Standard-17 Segment Reporting.

4. Business Outlook

Our Company is committed to delivering quality services while ensuring the safety of its employees and exercising business prudence. We will continue to dedicate our efforts toward achieving strong results within our scope of operations. The Company remains focused on enhancing productivity and efficiency, reducing costs, innovating service offerings, and developing profitable business streams. By optimizing resource utilization, we aim to steadily progress toward our strategic goals.

5. Internal Control system and their adequacy

The Company has established a well-defined internal control system that is adequate and commensurate with the size and nature of its business. An Internal Audit department is in place to ensure effective monitoring. Robust internal controls have been implemented to safeguard all assets against loss, misuse, or unauthorized disposal. Additionally, all transactions are duly authorized, accurately recorded, and properly reported. ERP-based controls further strengthen the reliability and integrity of the Company's financial and operational processes.

6. Discussion on financial performance with respect to operational performance

During the financial year ended March 31, 2026, the Company recorded an improvement in its operational and financial performance and returned to profitability on both standalone and consolidated basis.

On a standalone basis, revenue from operations increased to Rs. 18,163.64 thousand from Rs. 11,274.22 thousand in the previous financial year, registering an increase of approximately 61.11%. The Company reported Profit Before Tax of Rs. 252.58 thousand as against a Loss Before Tax of Rs. 27,190.57 thousand in the previous year. Profit After Tax stood at Rs. 1,198.11 thousand as compared to a Loss After Tax of Rs. 26,594.08 thousand in FY 2024-25. Earnings per Share (EPS) stood at Rs. 0.17 as against negative EPS of Rs. 4.21 in the previous year.

On a consolidated basis, revenue from operations stood at Rs. 18,163.64 thousand as compared to Rs. 11,274.22 thousand in the previous financial year. The Company reported Profit Before Tax of Rs. 137.01 thousand and Profit After Tax of Rs. 1,082.55 thousand, as against Loss Before Tax of Rs. 27,305.09 thousand and Loss After Tax of Rs. 26,708.60 thousand, respectively, in the previous financial year. Consolidated EPS stood at Rs. 0.15 as against negative EPS of Rs. 4.23 in FY 2024-25.

The improvement in performance during the year was reflected in the growth in revenue from operations and the Company's return to profitability. The Company continues to focus on strengthening its preclinical research and safety assessment services, improving operational efficiencies and pursuing business opportunities with a view to achieving sustainable growth.

7. Material developments in human resource/ industrial relations front, including number of people employed

The Company recognizes its human resources as an important contributor to its operations and growth. Considering the specialised nature of the Company's preclinical research and testing activities, emphasis continues to be placed on attracting, retaining and developing competent personnel and enhancing their technical and professional capabilities.

During the year under review, the Company continued to focus on employee development, training, workplace safety, productivity and maintaining a positive and collaborative work environment. Industrial relations remained cordial and harmonious throughout the year and there were no material developments on the human resources or industrial relations front that adversely affected the operations of the Company. As at March 31, 2026, the Company had 38 employees on its rolls.

8. Details of significant changes in key financial ratios, along with detailed explanation thereof

Particulars	Standalone basis		Consolidated basis	
	FY 2025-26	FY 2024-25	FY 2025-26	FY 2024-25
Debtors turnover ratio	0.71	0.65	0.71	0.65
Inventory turnover ratio	NA	NA	NA	NA
Debt Service Coverage Ratio	0.14	(0.39)	0.12	(0.41)
Current ratio	1.28	0.56	1.20	0.53
Debt equity ratio	1.79	1.78	1.80	1.79
Trade Payables Turnover Ratio	0.10	0.02	0.09	0.02
Operating profit margin (%)	44.19%	(184.41)%	43.55%	(183.43)%
Net Profit margin (%)	6.60%	(235.88)%	5.96%	(236.90)%
Return on Equity/Net worth (%)	1.68%	(42.13) %	1.52%	(42.31) %

Reason for more than 25% change in Inventory turnover ratio and Interest coverage ratio

Consolidated basis: The Inventory Turnover Ratio is not applicable to the Company and hence no variation is reported. The Interest Coverage Ratio improved significantly during FY 2025-26, primarily due to the improvement in operating performance and the Company returning to profitability during the year, as compared to the losses incurred in the previous financial year. Consequently, the earnings available for servicing finance costs improved substantially.

Standalone basis: The Inventory Turnover Ratio is not applicable to the Company and hence no variation is reported. The Interest Coverage Ratio improved significantly during FY 2025-26, mainly on account of improved operating results and the turnaround from losses in FY 2024-25 to profitability in FY 2025-26. The improvement in earnings resulted in better coverage of finance costs during the year.

Kindly refer financial statements and notes for further details

9. **Details of any change in return on net worth as compared to the immediately previous financial year Standalone Basis:**

The Return on Net Worth improved from (42.13) % in FY 2024-25 to 1.68% in FY 2025-26. The significant improvement is primarily attributable to the Company returning to profitability during the year, with Profit After Tax of Rs. 1,198.11 thousand, as against a Loss After Tax of Rs. 26,594.08 thousand in the previous financial year.

Consolidated Basis:

The Return on Net Worth improved from (42.31) % in FY 2024-25 to 1.52% in FY 2025-26. The improvement was mainly due to the turnaround in financial performance, with consolidated Profit After Tax of Rs. 1,082.55 thousand during FY 2025-26 as against a Loss After Tax of Rs. 26,708.60 thousand in FY 2024-25.

10. Disclosure of Accounting Treatment

The financial statements have been prepared in accordance with the Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Accounting Standards) Rules, 2021, and other generally accepted accounting principles in India, as applicable. The Company has not followed any accounting treatment different from that prescribed in the applicable Accounting Standards requiring explanation in this Management Discussion and Analysis. There has been no deviation in the accounting treatment from that prescribed in the Accounting Standards.

Cautionary Statement:

This report contains forward-looking statements extracted from reports of Government Authorities / Bodies, Industry Associations etc. available on the public domain which may involve risks and uncertainties including, but not limited to, economic conditions, government policies, dependence on certain businesses and other factors. Actual results, performance or achievements could differ materially from those expressed or implied in such forward-looking statements. This report should be read in conjunction with the financial statements included herein and the notes thereto. We assume no responsibility to publicly amend, modify or revise any such statements on the basis of subsequent developments, information or events.

For and on behalf of the Board
Vanta Bioscience Limited

Sd/-	**Sd/-**
Dopesh Raja Mulakala	**Padmanabhuni Venkata Appaji**
Managing Director	Director
DIN: 01176660	DIN: 02614167

Place: Hyderabad
Date: 05.09.2026

INDEPENDENT AUDITOR'S REPORT

To the Members of Vanta Bioscience Limited

Report on the Audit of the Standalone Financial Statements

Opinion:

We have audited the Standalone Financial Statements of Vanta Bioscience Limited which comprise the Balance Sheet as at 31st March 2026, the Statement of Profit and Loss,Statement of changes in Equity,Statement of Cash Flows for the year then ended, and Notes to the Standalone Financial Statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, theaforesaid StandaloneFinancial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

a) In the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2026;

b) In the case of the Statement of Profit and Loss Account, of the Profit for the period ended on that date and

c) In the case of the Statement of Cash Flow, of the cash flows, for the period ended on that date.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of theStandalone Financial Statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter:

We draw attention to Note No. 46 of the financial statements, which describes the Non - Provision for Gratuity.Our opinion is not modified in this matter.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon:

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors' Report and the Annexures thereto, but does not include the Standalone Financial Statements and our Auditor's Report thereon. The Directors Report is expected to be made available to us after the date of this Auditor's Report.

Our opinion on the Standalone Financial Statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the Standalone Financial Statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. When we read the Directors' Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and describe actions applicable in the applicable laws and regulations.

Management's Responsibility for the Standalone Financial Statements:

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of theseStandalone Financial Statements that give a true and fair view of the financial position, financial performance, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguardingof the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing theStandalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements:

1) As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanation given to us, we give "Annexure-A" a statement on the matters specified in the paragraphs 3 and 4 of the Order to the extent applicable to the company.

2) As required by Section 143(3) of the Act, we report that:

   (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

   (c) The Balance Sheet, the Statement of Profit and Loss, and the Statement of Cash Flow dealt with by this Report are in agreement with the books of account.

   (d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

(e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) In our opinion and to the best of our information and according to the explanations given to us, we are of the opinion that the company has adequate internal financial controls system in place and the operating effectiveness of such controls. Refer to our separate report in "Annexure - B".

With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position..

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no such amounts which were required to be transferred to the Investor Education and Protection Fund by the Company. There has been no delay in transferring to the Investor Education and Protection Fund by the Company.

iv. (a) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested either from borrowed funds or share premium or any other sources or kind of funds by the Company to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been received by the Company from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on such audit procedures that we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

v. The Company has not declared or paid any dividend during the year hence compliance with provisions of Section 123 of the Companies Act 2013 does not arise.

vi. Based on our examination, which include test checks, the Company has used accounting software for maintaining its books of account for the financial ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

Our examination of the audit trail was in the context of an audit of financial statements carried out in accordance with the Standard of Auditing and only to the extent required by Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014. We have not carried out any audit or examination of the audit trail beyond the matters required by the aforesaid Rule 11(g) nor have we carried out any standalone audit or examination of the audit trail.

3) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of Section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its Directors during the year is in accordance with the provisions of Section 197 read with Schedule V to the Act and is not in excess of the limit laid down under this Section and Schedule V of the Act.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

Place: Hyderabad
Date: 30.05.2026
UDIN: 26026967IGLVCK6315

Sd/-
B. V. RAMANA REDDY
M. No. 026967 Partner

ANNEXURE-A TO INDEPENDENT AUDITOR'S REPORT

Re: VANTA BIOSCIENCE LIMITED

Referred to in Paragraph 1 under section (Report on other Legal and Regulatory Requirements of our Report of even date)

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of Intangible Assets.

(b) The Property, Plant and Equipment of the company have been physically verified by the management at reasonable intervals during the year and no material discrepancies were noticed on such verification.

(c) According to the information and explanation given to us, the title deeds of the immovable properties (other than properties where the company is the lessee and the lease agreements are duly executed in favour of the lessee) are held in the name of the company.

(d) The Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to the information and explanation given to us, no proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and rules made there under during the year.

(ii) (a) The management has conducted physical verification of inventory at reasonable intervals during the year. In our opinion, the coverage and procedure of such verification by the management is appropriate. As informed to us, any discrepancies of 10% or more in the aggregate for each class of inventory were not noticed on such verification.

(b) The Company does not have any working capital limits in excess of five crore rupees (at any point of time during the year), in aggregate, from banks or financial institutions on the basis of security of current assets. Accordingly, the provisions of clause 3(ii) of the Order are not applicable.

(iii) During the year the company has made investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties:

(a) during the year the company has provided loans or provided advances in the nature of loans, or stood guarantee, or provided security to any other entity. The details are as follows:

Rupees in Thousands

To whom	The aggregate amount during the year	Balance outstanding at the balance sheet date
Parties other than subsidiaries, joint ventures and associates	203.26	44.53
Subsidiaries, joint ventures and associates	40,497.88	36,143.91

(b) According to the information and explanation given to us, the investments made, guarantees provided, security given and the terms and conditions of the grant of all loans and advances in the nature of loans and guarantees provided are not prejudicial to the company's interest;

(c) Schedule of repayment of the principal amount and the payment of the interest have not been stipulated and hence we are unable to comment as to whether receipt of the principal amount and the interest is regular;

(d) According to the information and explanation given to us, no amount is overdue in these respect;

(e) According to the information and explanation given to us, in respect of any loan or advance in the nature of loan granted no amount has fallen due during the year, hence renewal or extension or grant of fresh loans to settle the over dues of existing loans given to the same parties does not arise;

(f) The company has granted loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment, required details in respect thereof are as below:

Rupees in Thousands

The aggregate amount	Percentage thereof to the total loans granted	Aggregate amount of loans granted to Promoters, related parties as defined in clause (76) of section 2 of the Companies Act, 2013
36,188.44	100%	36,143.91

(iv) According to the information and explanation given to us, the company has complied with requirements of section 185 and 186 in respect of loans, investments, guarantees or security made by it during the year under audit;

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits under the directives of the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Companies Act, 2013 and the rules framed thereunder, where applicable. Accordingly, the provisions of clause 3(v) of the Order are not applicable.

(vii) To the best of our knowledge and belief, the Central Government has not specified maintenance of cost records under sub-section (1) of Section 148 of the Act, in respect of Company's products/ services. Accordingly, the provisions of clause 3(vi) of the Order are not applicable.

(vii) (a) The Company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues, as applicable, with the appropriate authorities except in caseof provident fund, employees' state insurance, professional tax and TDS. Further,no undisputed amounts payable in respect thereof were outstanding at the yearendfor a period of more than six months from the date they became payable except in case of provident fund, professional tax and TDS.

(b) There are no dues in respect of Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues that have not been deposited with the appropriate authorities on account of any dispute. .

(viii) According to the information and explanation given to us, company has no transactions, not recorded in the books of account have been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (43 of 1961);

(ix) (a) In our opinion, the company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender during the year;

(b) Company is not declared willful defaulter by any bank or financial institution or other lender;

(c) According to the information and explanation given to us, term loans were applied for the purpose for which the loans were obtained;

(d) According to the information and explanation given to us, funds raised on short term basis have not been utilised for long term purposes;

(e) According to the information and explanation given to us, the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures;

(f) According to the information and explanation given to us, the company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies;

(x) (a) The Company has not raised moneys by way of initial public offer or further public offer (including debt instruments) during the year;

(b) According to the information and explanation given to us, the Company hasmade preferential allotment of 8,00,000 shares (@ Rs. 50/- per share) during the year.The requirements of Section 42 and Section 62 of the Companies Act, 2013 wherever applicable have been complied with and the funds raised have been used for the purposes for which the funds were raised.

(xi) (a) According to the information and explanation given to us, any fraud by the company or any fraud on the company has not been noticed or reported during the year;

(b) According to the information and explanation given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government;

© According to the information and explanation given to us, no whistle-blower complaints, received during the year by the company;

(xii) Company is not a Nidhi company, accordingly provisions of the Clause 3(xii) of the Order is not applicable to the company;

(xiii) According to the information and explanations given to us, we are of the opinion that all transactions with related parties are in compliance with Section 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc., as required by the Accounting Standards and the Companies Act, 2013.

(xiv) (a) According to the information and explanations given to us, the company has an internal audit system commensurate with the size and nature of its business;

(b) We have considered the reports of the Internal Auditors for the period under audit;

(xv) According to the information and explanations given to us, we are of the opinion that the company has not entered into any non-cash transactions with directors or persons connected with him and accordingly, the provisions of clause 3(xv) of the Order is not applicable.

(xvi) According to the information and explanations given to us, we are of the opinion that the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934 and the company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India, accordingly the provisions of clause 3(xvi) of the Order are not applicable;

(xvii) According to the information and explanations given to us and based on the audit procedures conducted we are of opinion that the Company has not incurred any cash losses in the financial year but has incurred cash losses to an extent of Rs. 22,790.00 Thousands during the immediately preceding financialyear.

(xviii) There has been no resignation of the statutory auditors during the year and accordingly, the provisions of clause 3(xviii) of the Order is not applicable;

(xix) On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that company is incapable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) The provisions of Section 135 towards corporate social responsibility are not applicable on the company. Accordingly, the provision of clause 3(xx) of the Order is not applicable.

(xxi) The reporting under clause (xxi) is not applicable in respect of audit of standalone financial statements of the Company. Accordingly, no comment has been included in respect of said clause under this report.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

Place: Hyderabad
Date: 30.05.2026

Sd/-
B. V. RAMANA REDDY
M. No. 026967 Partner

ANNEXURE-B TO THE INDEPENDENT AUDITOR'S REPORT

Re: VANTA BIOSCIENCE LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **VANTA BIOSCIENCE LIMITED**(“the Company”) as of 31st March 2026 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls:

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility:

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting:

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting:

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion:

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

Place: Hyderabad
Date: 30.05.2026

Sd/-
B. V. RAMANA REDDY
M. No. 026967 Partner

BALANCE SHEET AS ON 31.03.2026

Rupees in Thousands

Particulars	Note No	As at 31.03.2026	As at 31.03.2025
1. Equity and Liabilities			
I. Share holder's Funds			
a) Share Capital	3	71,120.00	63,120.00
b) Reserves & Surplus	4	1,41,411.80	1,08,213.69
		2,12,531.80	**1,71,333.69**
II. Share Application Money pending allotment		**-**	**-**
III. Non Current Liabilities			
a) Deferred Tax Liabilities (Net)	5	6,481.52	7,427.05
b) Long Term Borrowings	6	3,12,076.16	1,93,913.17
c) Other Long Term Liabilities	7	12,500.00	-
d) Long Term Provisions		-	-
		3,31,057.68	**2,01,340.22**
IV. Current Liabilities			
a) Short Term Borrowings	8	68,706.16	1,10,800.07
b) Trade Payables	9	15,435.43	26,947.84
c) Other Current Liabilities	10	33,411.79	47,956.69
d) Short Term Provisions		-	-
		1,17,553.38	**1,85,704.60**
Total		**6,61,142.86**	**5,58,378.51**
2. Assets			
I. Non Current Assets			
a) Property, Plant & Equipment & Intangible Assets			
Property, Plant & Equipment	11	96,768.85	1,08,977.63
Intangible Assets	11	3,84,001.56	3,15,370.83
Capital WIP		-	-
b) Non Current Investments	12	30,000.00	30,000.00
c) Deferred Tax Assets(Net)		-	-
d) Long Term Loans and Advances		-	-
e) Other Non Current Assets	13	94.22	94.22
		5,10,864.63	**4,54,442.68**
II. Current Assets			
a) Current Investments		-	-
b) Inventories	14	75,274.60	64,826.76
c) Trade Receivables	15	25,583.50	17,447.53
d) Cash & Cash Equivalents	16	1,292.28	1,413.51
e) Short Term Loans & Advances	17	42,795.29	15,524.47
f) Other Current Assets	18	5,332.56	4,723.56
		1,50,278.23	**1,03,935.83**
Total		**6,61,142.86**	**5,58,378.51**

See accompanying notes to the financial statements
As per our report of even date annexed.

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board of Directors
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P. Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
CFO

Statement of Profit & Loss for the year ending 31.03.2026

Rupees in Thousands

Particulars	Note No	For the period ended 31.03.2026	For the period ended 31.03.2025
Revenue			
a) Revenue from Operations	19	18,163.64	11,274.22
b) Other Income	20	1,594.87	391.75
Total Income		**19,758.51**	**11,665.97**
Expenses			
a) Cost of Material consumed	21	1,412.49	734.92
b) Purchases of Stock in Trade		-	-
c) Changes in Inventories: Work in Progress	22	(10,337.80)	9,895.38
d) Employee Benfit Expenses	23	6,114.47	5,827.86
e) Finance Cost	24	7,773.20	6,625.82
f) Depreciation and Amortization Expenses	25	3,877.19	4,400.57
g) Other Expenses	26	10,666.38	11,371.99
Total Expenses		**19,505.93**	**38,856.54**
Profit Before Tax		**252.58**	**(27,190.57)**
Tax Expenses			
a) Current Tax		-	
b) MAT Credit Availed		-	
c) Deferred Tax	5	(945.53)	(596.49)
Total		**(945.53)**	**(596.49)**
Net profit for the year		**1,198.11**	**(26,594.08)**
Earning per Equity Share (In Rupees)			
1. Basic		0.17	(4.21)
2. Diluted		0.17	(4.21)

See accompanying notes to the financial statements
As per our report of even date annexed.

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board of Directors
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Place: Hyderabad
Date : 30.05.2026

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P. Venkata Appaji
Director
DIN: 02614167

Sd/-
pooja Kothari
Company Secretary

Sd/-
DVS Murali
CFO

Statement of Cash Flow for the year ended 31st March 2026

Rupees in Thousands

Particulars	For the period ended 31.03.2026	For the period ended 31.03.2025
A. Cash Flow from Operating Activities		
Profit before exceptional , Extraordinary items and Tax	252.58	(27,190.57)
Adjustment for:		
Depreciation	12,301.78	12,296.91
Finance Charges	7,773.20	6,625.82
Profit on Sale of Fixed Assets	-	
Sub total	**20,074.98**	**18,922.73**
Operating profit Before Working Capital Changes	**20,327.56**	**(8,267.85)**
Adjustment for:		
(Increase) /Decrease in Inventories	(10,447.84)	10,021.09
(Increase) /Decrease in Trade receivables	(8,135.97)	5,924.93
Increase /(Decrease) in Current Liabilities	(26,057.31)	5,558.11
(Increase) /Decrease Loans & Advances	(27,879.82)	378.48
(Increase) /Decrease in Current Investment	-	-
Sub total	**(72,520.94)**	**21,882.61**
Cash Generated from operations	**(52,193.38)**	**13,614.77**
Net Cash Flow from Operarting Activities	**(52,193.38)**	**13,614.77**
B: Cash Flow from Investing Activities		
Purchase of Fixed Assets	(93.00)	
Capital Work In progress	-	-
Capital Work In progress - R&D	(68,630.73)	(57,900.60)
Proceeds from sale of Fixed Assets	-	
Investment in Subsidiaries	-	-
Purchase of other Non current Investments	-	-
Net Cash Flow from Investing Activites	**(68,723.73)**	**(57,900.60)**
C: Cash Flow from Financing Activites		
Increase /(Decrease) in Working capital	(42,093.91)	38,119.15
Increase /(Decrease) in Term Loan	1,18,162.99	12,792.50
Increase /(Decrease) Other Long Term Liabilities	12,500.00	-
Increase /(Decrease) in share capital	8,000.00	-
Increase /(Decrease) in share Premium	32,000.00	-
Finance Charges	(7,773.20)	(6,625.82)
Net Cash Flow from Financing Activities	**1,20,795.88**	**44,285.84**
Actual Payment of Income Tax	-	-
D: Net Increase/Decrease in Cash and cash Equivalents	**(121.23)**	**-**
Opening of Cash & Cash Equivalents	**1,413.51**	**1,413.51**
Closing Balance of Cash & Cash Equivalents	**1,292.28**	**1,413.51**

See accompanying notes to the financial statements
As per our report of even date annexed.

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board of Directors
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P. Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
CFO

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

NOTE No. 1: CORPORATE INFORMATION:

VANTA BIOSCIENCELIMITED ("The Company") was incorporated as Private Limited Company on 29thApril, 2016, subsequently it was converted as a Public Limited Company on 17th March, 2017 and thereafter it is listed with BSE SME and the CIN being L74999TG2016PLC109280. The Company presently engaged in the business of Preclinical Activities.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES:

a) Basis of Accounting:

The financial statements have been prepared and presented under the historic cost convention on accrual basis to comply in all material respects with the notified Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The Accounting Policies have been consistently applied by the Company and are consistent with those used in the previous year. All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III of the Companies Act, 2013.

b) Use of Estimates:

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets, and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of Assets or Liabilities in the Future periods.

c) Property, Plant and Equipments:

Fixed assets are stated at cost less depreciation. All costs (excluding GST and Subsidy), including financing costs till commencement of commercial production and adjustments arising from exchange rate variations relating to borrowings attributable to the fixed assets are capitalized.

d) Depreciation:

The Company has provided depreciation for all the assets using Straight Line method as per the provisions specified in the Schedule II of the Companies Act, 2013.

e) Inventories:

Inventories have been taken as valued and certified by the Management. The basis of valuation is as under:

Raw materials, Stores & Spares - at cost or net realizable value whichever is lower.

Finished goods – at cost or net realizable value on FIFO basis whichever is lower.

f) Retirement benefits:

(i) Company's contribution to provident fund is charged to Profit & Loss Account.

(ii) Provision has been made in accounts for the future payment of gratuity to the employees of the Company, Pursuant to the payment of Gratuity Act, 1972 however provision has not been made based on the actuarial valuation.

g) Revenue recognition:

Income from operations is accounted Inclusive of GST on accrual basis.

i) Dividend from investments is recognized when the right to receive the payment is established.

ii) Interest income is recognized on a time proportion basis taking into account the amount outstanding and the applicable interest rate. Interest income is included under the head "other income-" in the statement of profit and loss.

iii) Revenue accrued, but not due at the end of financial year is recognized on proportionate completion basis in profit & Loss Account as per AS-7.

h) Investments:

Current Investments are valued at cost or market price whichever is lower and in the absence of market quotation, cost price is adopted. Long Term Investments are valued at cost.

I) R&D Expenditure:

Capital expenditure is included in the fixed assets and depreciation as per Company's policy.

Revenue expenditure is charged to profit & loss account of the year in which they are incurred and included in the respective heads of expenditure.

j) **Borrowing Costs:**

Borrowings costs that are directly attributable to the acquisition of qualifying assets are capitalized as part of cost of such asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.

k) **Cash Flow Statement:**

The Cash Flow Statement has been compiled with and is based on the Balance Sheet as at 31st March, 2024 and the related Profit and Loss Account for the year ended on that date. The Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard-3 on Cash Flow statement issued by ICAI.

l) **Accounting for Taxes on Income:**

Current Tax: Provision for Current Income Tax is made on the basis of the taxable income for the year as determined in accordance with the provisions of Income Tax Act, 1961.

Deferred Tax: Deferred income tax is recognized, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. The tax effect is calculated on the accumulated timing differences at the year-end based on tax rates and laws. Enacted or substantially enacted as of the Balance Sheet date.

m) **Impairment of Assets:**

The management assesses using external and internal sources whether there is any indication that an asset may be impaired. Impairment of an asset occurs where the carrying value exceeds the present value of cash flow expected to arise from the continuing use of the asset and its eventual disposal. The provision for impairment loss is made when recoverable amount of the asset is lower than the carrying amount.

n) **Provisions and Contingent Liabilities and Contingent Assets:**

Provisions in respect of present obligations arising out of past events are made in the accounts when reliable estimate can be made of the amount of obligations and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but if material, are disclosed in the notes to accounts. Contingent assets are not recognized or disclosed in the financial statements.

o) **Cash and Cash Equivalents:**

Cash and cash equivalents comprise of cash at bank and cash in hand. The Company considers all highly liquid investments with an original maturity of three months or less from date of purchase, to be cash equivalents.

p) **Intangible Assets:**

Intangible assets are stated at acquisition cost, net of accumulated amortization and accumulated impairment losses, if any. Intangible assets are amortized as per Accounting Standard 26.

q) **Earnings per share:**

Basic earnings per share are calculated by dividing the net profit for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The number of shares used in computing diluted earnings per share comprises the weighted average number of shares considered for deriving basic earnings per share and also the weighted average number of equity shares, which may be issued on the conversion of all dilutive potential shares, unless the results would be anti-dilutive.

r) **Foreign Currency Transactions:**

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of the transaction. Net exchange gain or loss resulting in respect of foreign exchange translations settled during period is recognized in the profit & loss account except for the net exchange gain or loss on account of imported fixed assets, which is adjusted in the carrying amount of the related fixed assets. Foreign currency denominated current assets and current liabilities at the period end are translated at the period end exchange rates and the resulting net gain or loss is recognized in the profit & loss account, except for exchange difference related to fixed assets purchased from foreign countries is adjusted in the carrying amount of related fixed assets.

Note No: 3 Share Capital

Particulars	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	Rupees in Thousands	No. of Shares	Rupees in Thousands
a) Share Capital				
Authorized	75,00,000	75,000.00	75,00,000	75,000.00
Equity Shares of Rs. 10 Each				
Issued, Subscribed and fully paid up	71,12,000	71,12,000	63,12,000	63,120.00
Equity Shares of Rs. 10 Each				
Total	**71,12,000**	**71,12,000**	**63,12,000**	**63,120.00**

b) Reconcilation of the number of shares and amount outstanding at the beginning and at the end of the reporting period

Particulars	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	Rupees in Thousands	No. of Shares	Rupees in Thousands
Equity Shares outstanding at the beginning of the year	63,12,000	63,120.00	63,12,000	63,120.00
Equity Shares Issued during the year	8,00,000	8,00,000	-	-
Total	**71,12,000**	**71,12,000**	**63,12,000**	**63,120.00**

c) Terms/ Rights attached to Equity Shares

The company has only one class of equity shares having par value of Rs. 10 Per share. Each holder of equity share is entitled to one vote per share.

d) Details of share held by each share Holder holding more than 5% Equity Shares

Name of the Share holder	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	Rupees in Thousands	No. of Shares	Rupees in Thousands
Mulakala Mohan krishna	34,85,500	34,855.00	34,85,500	34,855.00
Mulakala Dopesh Raja	858000	8,580.00	4,58,000	4,580.00
S CHANDRA SEKHAR RAO	5,22,500	5,225.00	1,22,500	1,225.00
Total	**48,66,000**	**48,660.00**	**40,66,000**	**40,660.00**

e) Details of shares held by promoters at the end of the year along with % of change

Name of the Promoter	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	% of total shares	No. of Shares	% of total shares
MOHAN KRISHNA MULAKALA	3485500	49.01	3485500	55.22
PRADEEP CHOWDARY VEERAMACHINENI	21500	0.30	21500	0.34
DOPESH RAJA MULAKALA	85800	12.06	458000	7.26
VYASMURTI MADHAVRAO SHINGATGERI	50000	0.70	50000	0.79
MULAKALA KARISHMA	50100	0.70	50100	0.79
SHRAVAN CHINTAPATLA	80100	1.13	80100	1.27
S CHANDRA SEKHAR RAO	522500	7.35	122500	1.94
M SAJAN KIRAN	20100	0.28	20100	0.32
SOUMYA SIMHADRI	90100	1.27	90100	1.43
SUJANA SHEELA MULAKALA	100	0.00	100	0.00

4. Reserves & Surplus

Particulars	As at 31.03.2026	As at 31.03.2025
Share Premium	1,84,120.00	1,52,120.00
General Reserve		
Balance as per the last Balance Sheet	-	-
Add: Transferred during the Year	-	-
Surplus in Profit & Loss Statement		
Balance as per the last Balance Sheet	(43,906.31)	(17,312.23)
Add: Transferred during the Year	1,198.11	(26,594.08)
Add: MAT Credit adjustment	-	-
Total	**1,41,411.80**	**1,08,213.69**

5. Deferred Tax Liability

Particulars	As at 31.03.2026	As at 31.03.2025
Opening Balance	7,427.05	8,023.54
Add: During the Year	(945.53)	(596.49)
Deferred Tax Liability	**6,481.52**	**7,427.05**

6. Long Term Borrowings

Particulars	As at 31.03.2026	As at 31.03.2025
Term Loan		
From Banks and from Financial Institutions		
Secured Borrowings		
Term Loan from State Bank of India	40,625.88	92,451.22
Unsecured Loans		
Loans from Directors and Related parties	3,12,076.16	1,54,128.00
Less: Amount disclosed under the head Short Term Borrowings payable with in 1 year	40,625.88	52,666.05
Total	**3,12,076.16**	**1,93,913.17**

a. Term Loan from State bank of India, SME Branch, Saifabad is secured by the hypothecation of Plant & Machinery including Lab Equipment standing in the name of the Company and primary security of Plot No. K2 11th Cross, SIPCOT, Industrial Complex, Gummidipudi, Tamilnadu-601201

b. Collateral Security of Module A123 Quatrant3, 5th Floor, Cyber Towers, Madhapur, Serlingampally, Rangareddy-500050 and Personal Gurantee of two directors Mr. Mulakala Mohan Krishna and Mr.Mulakala Dopesh Raja

7. Other Long Tem Borrowings

Particulars	As at 31.03.2026	As at 31.03.2025
Security Deposits	12,500.00	-
Total	**12,500.00**	**-**

8. Short Tem Borrowings

Particulars	As at 31.03.2026	As at 31.03.2025
Unsecured Loans		
Secured Loans		
Cash Credit from State Bank of India	25,142.35	25,285.39
Working Capital Demand Loan	2,937.93	2,990.54
SBI TOD Loan A/c No.42307725188	-	29,858.09
Current Maturity on Term Loan	40,625.88	52,666.05
Total	**68,706.16**	**1,10,800.07**

The Cash Credit and Working Capital Demand Loan from State Bank of India, SME Branch, Saifabad is secured by way of hypothecation of Stocks, Book Debts, first charge on movable fixed assets and further guranteed by the directors..

9. Trade Payables

Particulars	As at 31 Mar, 2026				
	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Dues - MSME	-	-	-	-	-
Undisputed Dues - Others	4,791.02	1,046.41	1,440.32	8,157.68	15,435.43
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-
Total	**4,791.02**	**1,046.41**	**1,440.32**	**8,157.68**	**15,435.43**

Particulars	As at 31 Mar, 2025				
	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Dues - MSME	-	-	-	-	-
Undisputed Dues - Others	11,385.67	3,647.23	3,514.85	8,400.09	26,947.84
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-
Total	**11,385.67**	**3,647.23**	**3,514.85**	**8,400.09**	**26,947.84**

10. Other Current Liabilities

Particulars	As at 31.03.2026	As at 31.03.2025
Outstanding Interest on Term Loan	474.54	2,468.36
Outstanding Interest on GEC Loan	-	520.07
Outstanding Interest on Addl GEC Loan	31.27	360.58
Outstanding Liabilities	8,500.81	8,733.37
Salaries & Wages Payable	9,756.35	12,761.07
Interest Payable on Unsecured Loan	7,493.07	17,953.63
Statutory Liabilities Payable		
PF Payable	3,239.58	2,638.34
ESI Payable	20.10	40.01
Professional Tax Payble	623.81	535.80
GST Payable	24.06	34.56
TDS Payable	3,248.20	1,910.90
Total	**33,411.79**	**47,956.69**

NOTE 11 PROPERTY, PLANT & EQUIPMENT

(Fig. in Rupees)

DESCRIPTION	GROSS BLOCK					DEPRECIATION						NET BLOCK	
	As on 01-04-2025	During the Year		Capitalisation of Preoperative Expenses	Total as on 31-03-2026	As on 31-03-2025	For the period 31-03-2026	Depreciation transferred to Procees under Development	Depreciation charged to Profit & Loss	Adjustments/ Deletions	Total as on 31-03-2026	As on 31-03-2026	As on 31-03-2025
		Additions	Deletions										
Tangible Assets:													
LAND	11,750.80	-	-	-	11,750.80	-	-	-	-	-	-	11,750.80	11,750.80
BUILDING	60,017.24	-	-	-	60,017.24	14,679.87	1,900.55	1,520.44	380.11	-	16,580.42	43,436.82	45,337.37
PLANT & MACHINERY	31,272.00	-	-	-	31,272.00	14,648.60	1,980.56	1,584.45	396.11	-	16,629.16	14,642.84	16,623.40
LAB EQUIPMENT	59,455.78	52.00	-	-	59,507.78	33,508.48	5,650.59	4,520.47	1,130.12	-	39,159.07	20,348.71	25,947.30
MISC. FIXED ASSETS	1,543.19	-	-	-	1,543.19	1,107.40	146.60	-	146.60	-	1,254.00	289.19	435.79
COMPUTERS	4,473.90	41.00	-	-	4,514.90	4,435.68	23.01	-	23.01	-	4,458.69	56.21	38.22
ELECTRICAL EQUIPMENT	10,515.87	-	-	-	10,515.87	7,587.01	999.04	799.23	199.81	-	8,586.05	1,929.82	2,928.86
FURNITURE & FITTINGS	16,857.16	-	-	-	16,857.16	10,941.27	1,601.43	-	1,601.43	-	12,542.70	4,314.46	5,915.89
Capital Work in Progress	-	-	-	-	-	-	-	-	-	-	-	-	-
TOTAL	**1,95,885.94**	**93.00**	**-**	**-**	**1,95,885.94**	**86,908.31**	**12,301.78**	**8,424.59**	**3,877.19**	**-**	**99,210.09**	**96,768.85**	**1,08,977.63**
Previous Year	1,95,885.94	-	-	-	1,95,885.94	74,611.40	12,296.91	7,896.34	4,400.57	-	86,908.31	1,08,977.63	1,21,274.54
Intangible Assets:													
Research & Development	3,15,370.83	68,630.73	-	-	3,84,001.56	-	-	-		-	-	3,84,001.56	3,15,370.83
Total	**3,15,370.83**	**68,630.73**	**-**	**-**	**3,84,001.56**	**-**	**-**	**-**		**-**	**-**	**3,84,001.56**	**3,15,370.83**
Previous Year	2,57,470.23	57,900.60	-	-	3,15,370.83	-	-	-		-	-	3,15,370.83	2,57,470.23

12. Long Term Investments

Particulars	As at 31.03.2026	As at 31.03.2025
Investment in Vanta Clinical Research Limited [30,00,000 Shares of Rs. 10/- each (30,00,000 Shares of Rs. 10/- each) stated at cost]	30,000.00	30,000.00
Total	**30,000.00**	**30,000.00**

13. Other Non Current Assets

Particulars	As at 31.03.2026	As at 31.03.2025
Electricity Deposit	94.22	94.22
Total	**94.22**	**94.22**

14. Inventories

Particulars	As at 31.03.2026	As at 31.03.2025
Services / Method Under Process	74,930.38	64,592.58
Closing Stock of Material	344.22	234.18
Total	**75,274.60**	**64,826.76**

NOTE No. 15
TRADE RECEIVABLES

Particulars	As at 31 Mar, 2026					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables - Considered Good	-	-	-	-	-	-
Undisputed Trade Receivables - Considered Doubt	5,112.41	1,908.17	5,199.27	8,826.60	4,537.05	25,583.50
Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
Disputed Trade Receivables - Considered Doubt	-	-	-	-	-	-
Total	**5,112.41**	**1,908.17**	**5,199.27**	**8,826.60**	**4,537.05**	**25,583.50**

Particulars	As at 31 Mar, 2025					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables - Considered Good	450.10	4,760.33	8,041.25	3,005.60	1,190.25	17,447.53
Undisputed Trade Receivables - Considered Doubt	-	-	-	-	-	-
Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
Disputed Trade Receivables - Considered Doubt	-	-	-	-	-	-
Total	**450.10**	**4,760.33**	**8,041.25**	**3,005.60**	**1,190.25**	**17,447.53**

Particulars	As at 31 Mar, 2024					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables - Considered Good	13,909.12	5,350.87	2,932.93	404.61	774.93	23,372.46
Undisputed Trade Receivables - Considered Doubt	-	-	-	-	-	-
Disputed Trade Receivables - Considered Good	-	-	-	-	-	-
Disputed Trade Receivables - Considered Doubt	-	-	-	-	-	-
Total	**13,909.12**	**5,350.87**	**2,932.93**	**404.61**	**774.93**	**23,372.46**

16. Cash & Cash Equivalents

Particulars	As at 31.03.2026	As at 31.03.2025
In Current Accounts		-
Cash on Hand	1,292.28	1,413.51
Total	**1,292.28**	**1,413.51**

17. Short Term Loans & Advances

Particulars	As at 31.03.2026	As at 31.03.2025
Advances to Creditors	5,950.75	4,459.89
Staff Advance - Salary	44.53	521.18
Other Advances	36,143.91	9,286.99
GST Input Credit	656.10	1,256.41
Total	**42,795.29**	**15,524.47**

18. Other Current Assets

Particulars	As at 31.03.2026	As at 31.03.2025
Prepaid Expenses	334.62	241.78
IT Refund	754.65	238.49
MAT Credit	4,243.29	4,243.29
Total	**5,332.56**	**4,723.56**

19. Revenue from Operations

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
Revenue from Testing Analysis Service Charges(Domestic)	15,642.06	2,517.38
Revenue from Testing Analysis Service charges(Export)	2,305.68	8,756.84
Sale of Products	215.90	-
Total	**18,163.64**	**11,274.22**

20. Other Income

Particulars	For the year ended 31.03.2026	For the year ended 31.03.2025
Other Income	9.96	41.61
Foreign Exchange Fluctuation	1,584.91	350.14
Total	**1,594.87**	**391.75**

21. Consumption of Material

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Opening Stock of Materials	234.18	359.89
Add: Purchases		
Purchase of Lab Chemicals	85.38	40.87
Feed Cost	599.01	148.65
Purchase of Consumables	815.10	240.15
Purchase of Live Animals	9.10	161.75
Testing Charges	13.94	17.80
Sub Total	**1,756.71**	**969.10**
Less: Closing Stock	344.22	234.18
Total	**1,412.49**	**734.92**

22. Change in Inventory-Work in Progress

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Opening Method and process	64,592.58	74,487.96
Less: Closing Method and process	74,930.38	64,592.58
Total	**-10,337.80**	**9,895.38**

23. Employment Benefit Expenses

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Salaries & Wages	4,880.14	4,790.35
Staffwelfare Expenses	151.33	289.07
Contribution to PF	137.20	177.36
Contribution to ESI	16.20	12.73
Leave Encashment	383.31	-
Gratuity	172.96	-
Labour Charges	373.33	558.36
Total	**6,114.47**	**5,827.86**

24. Finance Cost

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Interest on Cash Credit	764.26	754.56
Interest on Term Loan	1,709.32	2,455.68
Interest on Working Capital Term Loan	201.76	455.75
Interest on GECL Loan	151.89	493.38
Interest on Others	491.03	8.30
Interest on Unsecured Loan	3,778.02	2,194.92
Bank Charges	33.86	81.51
Loan Processing Fee	643.06	181.72
Total	**7,773.20**	**6,625.82**

25. Depreciation and Amortisation Expenses

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Depreciation	3,877.19	4,400.57
Total	**3,877.19**	**4,400.57**

26. Other Expenses

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Factory Maintenance	64.64	86.52
Lab Maintenance	130.23	175.43
Repairs & Maintenance - P&M	171.19	283.68
Repairs & Maintenance - Others	162.39	241.54
Diesel Charges	131.28	221.69
Electricity Charges	1,685.12	2,295.30
Rent	63.72	63.72
Audit Fee		
Statutory Audit Fee	150.00	150.00
Internal Audit Fee	100.00	100.00
Audit Expenses	-	10.84
Business Development Expenses	233.49	1,795.20
Commission	931.28	335.34
Computer Expenses	191.29	182.48
Consultancy Charges	2,671.98	788.00
Conveyance	154.99	214.16
General Expenses	567.70	424.61
Insurance	207.33	205.56
Internet Expenses	28.00	26.28
Office Maintenance	0.75	108.11
Postage & Telegrams	63.09	61.99
Printing & Stationery	31.76	85.20
Rates & Taxes	296.16	389.72
Registration & Renewals	1.00	21.50
Safety Expenses	121.63	267.08
Security Expenses	700.05	743.83
Staff Recruitment Expenses	5.60	11.78
Subscription & Membership Fee	274.91	356.33
Telephone Expenses	31.93	44.02
Travelling Expenses	1,003.26	1,081.84
Carriage Outward - Local	54.70	-
Vehicle Hire Charges	436.91	600.26
Total	**10,666.38**	**11,371.99**

Note No. 27 : FINANCIAL RATIOS

Sl. No.	Ratio	Numerator	Denominator	2026	2025	% Variance	Reasons for variance of above 25%
1	Current Ratio (in times)	Current Assets	Current Liabilities	1.28	0.56	128.41	Variance is primarily on account of increase in current assets and decrease in current liabilities.
2	Debt - Equity Ratio (in times)	Total Debt	Total Equity	1.79	1.78	0.74	-
3	Debt Service Coverage Ratio (in times)	Earnings available for Debt Service	Debt Service	0.14	-0.39	-134.90	Variance is primarily on account of increase in profit and increase in debt serviced.
4	Return on Equity Ratio (in %)	Profit After Tax	Average Equity	1.68	-42.13	-104.00	Variance is primarily on account of increase in profit.
5	Inventory Turnover Ratio (in times)	Net Sales	Average Inventory	NA	NA	NA	-
6	Trade Receivables Turnover Ratio (in times)	Revenue from Operations	Average Trade Receivables	0.71	0.65	9.87	-
7	Trade Payables Turnover Ratio (in times)	Adjusted Expenses	Average Payables	0.10	0.02	336.32	Variance is primarily on account of increase in adjusted expenses and decrease in trade payables.
8	Net Capital Turnover Ratio (in times)	Revenue from Operations	Average Working Capital (i.e. Total current assets	0.56	-0.14	-502.56	Variance is primarily on account of increase in Revenue from Operations and positive working capital.
9	Net Profit Ratio (in %)	Profit After Tax	Revenue from Operations	6.60	-235.88	-102.80	Variance is primarily on account of increase in revenue and profits.
10	Return on Investment (in %)	Income generated from Investments	Average Investments	NA	NA	NA	-
11	Return on Capital Employed (in %)	Profit before tax and finance costs	Capital Employed = Net Worth + Lease Liabilities + Deferred Tax Liabilities	0.04	-0.12	-131.85	Variance is primarily on account of increase in profits and networth.

28. FOREIGN EXCHANGE TRANSACTIONS:

Rupees in Thousands

	Particulars	31 March 2026
A	Expenditure on Foreign Currency	NIL
B	Earnings on Foreign Currency	2,305.68
C	Foreign Exchange Gain	1584.91

29. CONTINGENT LIABILITIES: NIL

30. MANAGERIAL REMUNERATION: NIL

31. REMUNERATION TO AUDITORS:

Rupees in Thousands

Particulars	31 March 2026	31 March 2025
A. Statutory Auditor:		
Statutory Audit Fee	125.00	
Tax Audit Fee	25.00	
Total A		150.00
B. Internal Auditor:		
Internal Auditor Fee	100.00	
Total B		100.00
Total (A) and (B)		**250.00**

32. DEFERRED TAX:

Rupees in Thousands

	31 March 2026
In Conformity with the Accounting Standard 22 on Accounting for Taxes on income issued by Institute of Chartered Accountants of India, during the year the Company has provided for the Net Deferred Tax Liability/ Assets in the books of account.	
Net Block as per Companies Act	96,768.85
Net Block as per Income Tax Act	71,839.94
Timing Difference	24,928.91
Net Tax Liability as on 31-03-2026	6,481.52
Less: Deferred Tax Liability as on 31-03-2025	7,427.04
Effect on Profit and Loss Account (Deferred Tax Income for the year)	945.53

#Deferred Tax liability represents timing differences in depreciation on fixed assets

33. EARNING PER SHARE:

(A) BASIC EARNING PER SHARE

i.	Number of equity shares outstanding at the beginning of the year.	71,12,000
ii.	Number of equity shares issued during the year.	-NIL-
iii.	Total number of equity shares outstanding at the end of the year.	71,12,000
iv.	Profit available to share holders (Rupees in Thousands)	1,198.11
v.	Basic Earning per Share (Face value Rs. 10/-) in Rupees	0.17

(B) DILUTED EARNING PER SHARE

i.	Number of equity shares outstanding as per Point No. iii above.	71,12,000
ii.	Weighted average number of potential equity shares outstanding	-NIL-
iii.	Weighted average number of shares outstanding	71,12,000
iv.	Profit available to share holders (Rupees in Thousands)	1,198.11
v.	Diluted Earning per Share (Face value Rs. 10/-) in Rupees	0.17

34. RELATED PARTY TRANSACTIONS:

Disclosure as required by Accounting Standard AS 18: Related party disclosures issued by the Institute of Chartered Accountant of India (ICAI) are as follows:

S. No.	Name of the Related Party	Relation	Nature of Transaction	Volume of Transaction (Rupees in Thousands)	Closing Balance as on 31/03/2026 (Rupees in Thousands)
1.	Sarvotham Care	Promoter Director is the proprietor of the firm	Unsecured Loan received by the Company	0.00	800.00
2.	M.Sujana Sheela	Promoter's Spouse	Office Rent	63.72	504.65
3.	Sarvotham Remedies Limited	Promoter Directors are Directors of the Company	Unsecured Loan received by the Company & Interest on Loan	2,500.00 & 1,532.19	16,500.00 & Nil
4.	Sarvotham Solutions Limited	Promoter Directors are Directors of the Company	Unsecured Loan received by the Company & Interest on Loan	Nil & 3064.80	30,648.00 & Nil
5.	Sarvotham Care Limited	Promoter Directors are Directors of the Company	Unsecured Loan received by the Company & Interest on Loan	191,848.16 & 12,688.07	241,913.16 & 174.04
6.	Cebis India Limited	Step Subsidiary	Expenses of the Company incurred by Cebis India Limited	40,497.88	26,856.92
7.	Vanta Clinical Research Limited	Subsidiary Company	Repayment by the company	-	9,500.94
8.	Sri. M. Dopesh Raja	KMP	Unsecured Loan received by the Company 4,00,000 Shares issued @ Rs. per share	6,100.00& 20,000.00	8,915.00
9.	D V S Murali	KMP	Key Managerial Personal Compensation	442.79	67.60
10.	Sangeetha Padam Choudhary	KMP	Key Managerial Personal Compensation	210.00	0.00
11.	Pooja Kothari	KMP	Key Managerial Personal Compensation	60.00	30.00
12.	Simhadri Chandra Sekhar Rao	KMP	Unsecured Loan received by the Company & Interest on Loan 4,00,000 Shares issued @ Rs. 50/- per share & Interest on Loan	Nil, 20,000.00 & 1,487.26	12,900.00 & 7,319.04

35. SEGMENT REPORTING:

The Company is engaged in the business of full service preclinical contract research organization. Accounting Standard 17 "Segment Reporting" issued by the Institute of Chartered Accountants of India is not applicable.

36. **SHARE CAPITAL:**

The authorized capital of the company is Rs. 7,50,00,000/- divided into 75,00,000 equity shares of Rs. 10/- each.

Total Paid up Equity Share Capital of Rs. 7,11,20,000/- are divided into 71,12,000 equity shares of Rs. 10/- each.

37. The cash balance as on 31/03/2026 amounts to Rs.1,292.28Thousands. Since we could not undertake physical verification of cash on 31/03/2026 we have relied upon the certificate issued by the management in this regard.

38. In the view of Management, no event has taken place to trigger the need for testing its assets for impairment. Accordingly, as per the management's assessment, the carrying values of its assets as at the Balance sheet date are not higher than their corresponding recoverable amounts.

39. In the opinion of the Board the Current assets, Loans and advances are approximately of the value stated if realized in the ordinary course of the business. The provision for depreciation and all known liabilities are adequate and not in excess of the amount considered reasonably necessary.

40. Confirmation of balances has not been received from any of the Creditors, Debtors and for Loans & Advances, which are subject to reconciliation. Provision for doubtful debts, if any, in respect of the above and the consequential adjustment, if any, whether of revenue nature or otherwise, will be dealt accordingly.

41. **DISCLOSURE UNDER MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT**

Particulars	**For the Year ended March 31, 2026**		**For the Year ended March 31, 2025**	
	Principal	**Interest**	**Principal**	**Interest**
Amount due to Vendor	Nil	Nil	Nil	Nil
Principal amount paid (includes unpaid) beyond the appointed date	Nil	Nil	Nil	Nil
Interest due and payable for the period	Nil	Nil	Nil	Nil
Interest accrued and remaining paid	Nil	Nil	Nil	Nil

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of the information collected by management.

42. ADDITIONAL INFORMATION PURSUANT TO PARAGRAPHS 3&4 OFPART II OF SCHEDULE III TO THE COMPANIES ACT 2013, (AS CERTIFIED BY A DIRECTOR): NIL

43. The company has not proposed any dividend for the year under review.

44. During the year the following provisions were made:

Particulars	**Rupees in Thousands**
Current Tax	Nil

45. An amount of Rs. 68,630.73 Thousands was spent towards Research & Development during the year under review.

46. Provision for Gratuity has not been created for the period.

47. Previous year figures have been regrouped and rearranged wherever necessary.

48. All the amounts are rounded off to the nearest thousands.

As per our attached report of even date
For **Mathesh & Ramana**
Chartered Accountants

On behalf of the Board
For **Vanta Bioscience Limited**

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P. Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
DVS Murali
CFO

Sd/-
Pooja Kothari
Company Secretary

INDEPENDENT AUDITOR'S REPORT

To the Members of
VANTA BIOSCIENCE LIMITED

Report on the Audit of the Consolidated Financial Statements:

Opinion:

We have audited the accompanying Consolidated Financial Statements of VANTA BIOSCIENCE LIMITED (hereinafter referred to as “the Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as “the Group”), which comprise the Consolidated Balance Sheet as at March 31, 2026, and the Consolidated Statement of Profit and Loss, Consolidated Statement of Cash Flows, the Consolidated Statement of Changes in Equity for the year then ended, and Notes to the Consolidated Financial Statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as “the Consolidated Financial Statements”).

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the Consolidated State of Affairs of the Company as at March 31, 2026, Consolidated Profit, its Consolidated Cash Flows and Consolidated Changes in equity for the year then ended.

Basis for Opinion:

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter:

We draw attention to Note No. 44 of the financial statements, which describes that the Subsidiary of the Company has not yet started its operations till the date of this report.

We draw attention to Note No. 45 of the financial statements, which describes the Non - Provision for Gratuity in case of Holding and Subsidiary Company.

Our opinion is not modified in the above said matters.

Information Other than the Consolidated Financial Statements and Auditor’s Report Thereon:

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Directors' Report and the Annexures thereto, but does not include the Financial Statements and our Auditor's Report thereon. The Directors Report is expected to be made available to us after the date of this Auditor's Report.

Our opinion on the Consolidated Financial Statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the Consolidated Financial Statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. When we read the Directors' Report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and describe actions applicable in the applicable laws and regulations.

Responsibilities of Management and those charged with Governance for the Consolidated Financial Statements:

The Holding Company's Board of Directors are responsible for the matters stated in Section 134(5) of the Companies Act, 2013 (“the Act”) with respect to the preparation of these Consolidated Financial Statements in terms of the requirements of the Companies Act, 2013 (hereinafter referred to as “the Act”) that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Consolidated Financial Statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the Company is responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group is also responsible for overseeing the Company's financial reporting process of the Group.

Auditor’s Responsibilities for the Audit of the Consolidated Financial Statements:

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(I) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management’s use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor’s report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor’s report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group and its associates and jointly controlled entities to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated Financial Statements of which we are the Independent Auditors. For the other entities included in the Consolidated Financial Statements, which have been audited by other Auditors, such other Auditors remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Statements of which we are the Independent Auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our Auditor's Report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters:

We did not audit the financial statements / financial information of one subsidiary, whose financial statements / financial information reflect total assets of Rs.39,383.45Thousands as at 31st March, 2026 and net cash flows amounting to Rs.(0.65) Thousands for the year ended on that date, as considered in the Consolidated Financial Statements. The Consolidated Financial Statements also include the Group's share of Net Profit of Rs. (115.57) Thousands for the year ended 31st March 2026as considered in the Consolidated Financial Statements in respect of the Subsidiary whose financial statements / financial information have not been audited by us. These financial statements / financial information have been audited by other Auditors whose reports have been furnished to us by the Management and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and our report in terms of sub-section (3) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries, is based solely on the reports of the other Auditors.

Our opinion on the Consolidated Financial Statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other Auditors and the financial statements / financial information certified by the Management.

Report on Other Legal and Regulatory Requirements:

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 and on the basis of such checks of the books and records of the company as we considered appropriate and according to the information and explanation given to us, we give "Annexure-A" a statement on the matters specified in the paragraphs 3 and 4 of the Order to the extent applicable to the company.
2. As required by Section143(3) of the Act, we report, to the extent applicable, that:
   - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.
   - (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statements have been kept so far as it appears from our examination of those books and the reports of the other Auditors.
   - (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Statement of Cash Flow dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the Consolidated Financial Statements.
   - (d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act read with Rule 7 of the Companies (Accounts) Rules, 2014.
   - (e) On the basis of the written representations received from the Directors of the Holding Company as on 31st March, 2026 taken on record by the Board of Directors of the Holding Company and the reports of the Statutory Auditors of its Subsidiary Companies, none of the Directors of the Group Companies is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.
   - (f) With respect to the adequacy of Internal Financial Controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in Annexure-B.
   - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditor's) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
     - (i) There were no pending litigations which would impact the consolidated financial position of the Group.
     - (ii) The Group did not have any material foreseeable losses on long-term contracts including derivative contracts.
     - (iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its subsidiary companies.
     - (iv) (a) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been advanced or loaned or invested either from borrowed funds or share premium or any other sources or kind of funds by the Group to or in any other person or entity, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
       - (b) The management has represented that, to the best of its knowledge and belief, as disclosed in the notes to the accounts, no funds have been received by the Group from any person or entity, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing

or otherwise, that the Group shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(c) Based on such audit procedures that we considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

(v) The Holding Company and its Subsidiary has not declared or paid any dividend during the year hence compliance with provisions of Section 123 of the Companies Act 2013 does not arise.

(vi) Based on our examination, which include test checks, the Company has used accounting software for maintaining its books of account for the financial ended March 31, 2026 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with and the audit trail has been preserved by the company as per the statutory requirements for record retention.

Our examination of the audit trail was in the context of an audit of financial statements carried out in accordance with the Standard of Auditing and only to the extent required by Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014. We have not carried out any audit or examination of the audit trail beyond the matters required by the aforesaid Rule 11(g) nor have we carried out any standalone audit or examination ofthe audit trail.

3. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company to its Directors during the year is in accordance with the provisions of section 197 of the Act read with Schedule V of the Act and is not in excess of the limit laid down under this section and Schedule.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

Sd/-
B. V. RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad
Date: 30.05.2026
UDIN: 26026967AWTIAZ8387

ANNEXURE A TO INDEPENDENT AUDITOR'S REPORT OF CONSOLIDATED FINANCIAL STATEMENTS

Re: VANTA BIOSCIENCE LIMITED

Referred to in Paragraph 1 under section (Report on other Legal and Regulatory Requirements of our Report of even date)

(xxi) According to the information and explanations given to us, the Company has only one subsidiaries namely Vanta Clinical Research Limited (CIN: U73100TG2018PLC126673) whose financial statements have been included in the Consolidated Financial Statements. The paragraph numbers of the CARO Report of the Subsidiary Company containing the qualifications or adverse remarks are indicated below along with the qualifications or adverse remarks given by the Statutory Auditors of the Subsidiary Company.

Vanta Bioscience Limited:

Clause (iii) (a):

During the year the company has provided loans or provided advances in the nature of loans, or stood guarantee, or provided security to any other entity. The details are as follows:

Rupees in Thousands

To whom	The aggregate amount during the year	Balance outstanding at the balance sheet date
Parties other than subsidiaries, joint ventures and associates	203.26	44.53
Subsidiaries, joint ventures and associates	40,497.88	36,143.91

Clause (iii) (f):

The company has granted loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment, required details in respect thereof are as below: :

Rupees in Thousands

The aggregate amount	Percentage thereof to the total loans granted	Aggregate amount of loans granted to Promoters, related parties as defined in clause (76) of section 2 of the Companies Act, 2013
36,188.44	100%	36,143.91

Clause (vii)(a):

The Company is regular in depositing undisputed statutory dues including Goods and Services Tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues, as applicable, with the appropriate authorities except in case of provident fund, employees' state insurance, professional tax and TDS. Further, no undisputed amounts payable in respect thereof were outstanding at the yearend for a period of more than six months from the date they became payable except in case of provident fund, professional tax and TDS.

Clause (xvii):

According to the information and explanations given to us and based on the audit procedures conducted we are of opinion that the Company has not incurred any cash losses in the financial year but has incurred cash losses to an extent of Rs. 22,790.00 Thousands during the immediately preceding financial year.

Vanta Clinical Research Limited:

Clause (iii):

The Company has not made investments in, provided any guarantees or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or any other parties except for unsecured loan granted to its subsidiary during the previous year.

The aggregate amount of loan given was Nil and the amount outstanding at the end of the year was Rs. 88,39,940/-.

Clause (ix) (e):

According to the information and explanations given to us and on the basis of our examination of the books of account, there has been no movement of the amount during the yearin respect of the advance received from its parent company and the amount outstanding at the year-end was Rs. 95,00,339/-.

Clause (xvii):

In our opinion and to the best of our information and according to the explanations given to us and on the basis of examination of the books of account, as the Company had not yet started its operations,it has incurred cash losses during the year and in the immediately preceding financial year. However, the Management is confident that the operations will be started soon and accordingly, no adjustments have been made to the financial statementsand these have been prepared on a going concern basis.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

Sd/-
B. V. RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad
Date: 30.05.2026

ANNEXURE B TO INDEPENDENT AUDITOR'S REPORT

Re: VANTA BIOSCIENCE LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

In conjunction with our audit of the Consolidated Financial Statements of the Company as of and for the year ended 31st March, 2026, we have audited the internal financial controls over financial reporting of **VANTA BIOSCIENCE LIMITED**(hereinafter referred to as "the Holding Company") and have adopted the report on the internal financial controls over financial reporting issued by the respective Auditors of its Subsidiary Companies, which are companies incorporated in India, as of that date.

Management's Responsibility for Internal Financial Controls:

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility:

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of Internal Financial Controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate Internal Financial Controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the Internal Financial Controls system over financial reporting and their operating effectiveness. Our audit of Internal Financial Controls over financial reporting included obtaining an understanding of Internal Financial Controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's Internal Financial Controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting:

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting:

Because of the inherent limitations of Internal Financial Controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the Internal Financial Controls over financial reporting to future periods are subject to the risk that the Internal Financial Control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Internal Financial Controls over financial reporting of Subsidiaries have been audited by other Auditors whose reports have been furnished to us by the Management and our opinion on the Consolidated Internal Financial Controls over financial reporting, included in respect of these Subsidiaries and our report in terms of Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of Internal Financial Controls insofar as it relates to the aforesaid Subsidiaries, is based solely on the reports of the other Auditors.

Opinion:

In our opinion, the Company has, in all material respects, an adequate Internal Financial Controls system over financial reporting and such Internal Financial Controls over financial reporting were operating effectively as at 31 March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MATHESH & RAMANA**
CHARTERED ACCOUNTANTS

Sd/-
B. V. RAMANA REDDY
M. No. 026967 Partner

Place: Hyderabad
Date: 30.05.2026

CONSOLIDATED BALANCE SHEET AS ON 31.03.2026

Rupees in Thousands

Particulars	Note No	As at 31.03.2026	As at 31.03.2025
1. Equity and Liabilities			
I. Share holder's Funds			
a) Share Capital	3	71,120.00	63,120.00
b) Reserves & Surplus	4	1,40,636.14	1,07,553.59
		2,11,756.14	**1,70,673.59**
II. Share Application Money pending allotment		**-**	**-**
III. Non Current Liabilities			
a) Deferred Tax Liabilities (Net)	5	6,481.52	7,427.05
b) Long Term Borrowings	6	3,12,076.16	1,93,913.17
c) Other Long Term Liabilities	7	12,500.00	-
d) Long Term Provisions		-	-
		3,31,057.68	**2,01,340.22**
IV. Current Liabilities			
a) Short Term Borrowings	8	68,706.16	1,10,800.07
b) Trade Payables	9	16,089.20	36,978.02
c) Other Current Liabilities	10	33,416.79	47,961.69
d) Short Term Provisions		-	-
		1,18,212.15	**1,95,739.78**
Total		**6,61,025.97**	**5,67,753.59**
2. Assets			
I. Non Current Assets			
a) Property, Plant & Equipment & Intangible Assets			
Property, Plant & Equipment	11	96,768.85	1,08,977.63
Intangible Under Development		-	-
Intangible Assets	11	3,84,001.56	3,15,370.83
Capital WIP		-	-
b) Non Current Investments	12	30,000.00	30,000.00
c) Deferred Tax Assets(Net)		-	-
d) Long Term Loans and Advances	13	8,839.94	8,839.94
e) Other Non Current Assets	14	94.22	94.22
		5,19,704.57	**4,63,282.62**
II. Current Assets			
a) Current Investments		-	-
b) Inventories	15	75,274.60	64,826.76
c) Trade Receivables	16	25,583.51	17,447,.53
d) Cash & Cash Equivalents	17	1,354.60	1,476.48
e) Short Term Loans & Advances	18	33,776.13	15,966.64
f) Other Current Assets	19	5,332.56	4,723.56
		1,41,321.40	**1,04,470.97**
Total		**6,61,025.97**	**5,67,753.59**

See accompanying notes to the financial statements
As per our report of even date annexed.

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board of Directors
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P.Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
Chief Financial Officer

CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31ST MARCH, 2026

Rupees in Thousands

Particulars	Note No	For the period ended 31.03.2026	For the period ended 31.03.2025
Revenue			
a) Revenue from operations	20	18,163.64	11,274.22
b) Other Income	21	1,594.87	391.75
Total Income		**19,758.51**	**11,665.97**
Expenses			
a) Cost of material consumed	22	1,412.49	734.92
b) Purchases of Stock in Trade		-	-
c) Changes in Inventories: Work in Progress	23	-10,337.80	9,895.38
d) Employee Benfit Expenses	24	6,114.47	5,827.86
e) Finance Cost	25	7,773.19	6,625.82
f) Depreciation and Amortization Expenses	26	3,877.19	4,400.57
g) Other Expenses	27	10,781.95	11,486.51
Total Exp		**19,621.49**	**38,971.06**
Profit Before Tax		137.02	-27,305.09
Tax Expenses			
a) Current Income Tax		-	-
b) MAT Credit Availed		-	-
c) Deferred Tax	5	-945.53	-596.49
Total		**-945.53**	**-596.49**
Net profit for the year		**1,082.55**	**-26.708.60**
Earning per Equity Share (In Rupees)			
1. Basic		0.15	(4.23)
2. Diluted		0.15	(4.23)

See accompanying notes to the financial statements
As per our report of even date annexed.

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board of Directors
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P.Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
Chief Financial Officer

Consolidated Statement of Cash Flow for the year ended 31st March 2026

Rupees in Thousands

Particulars	For the period ended 31.03.2026	For the period ended 31.03.2025
A. Cash Flow from Operating Activities		
Profit before exceptional, Extraordinary items and Tax	137.02	(27,305.09)
Adjustment for:		
Depreciation	12,301.78	12,296.91
Finance Charges	7,773.19	6,625.82
Profit on Sale of Fixed Assets	-	-
Sub total	**20,074.97**	**18,922.73**
Operating profit Before Working Capital Changes	**20,211.99**	**(8,382.36)**
Adjustment for:		
(Increase) /Decrease in Inventories	(10,447.84)	10,021.09
(Increase) /Decrease in Trade Receivables	(8,135.98)	5,924.93
Increase /(Decrease) in Current Liabilities	(35,433.72)	5,674.10
(Increase) /Decrease Loans & Advances	(18,388.49)	369.48
Increase /(Decrease) in Current Assets	-	-
(Increase) /Decrease Current Investment	-	-
(Increase) /Decrease in Non Current Assets	-	-
Sub total	**(72,406.03)**	**21,989.60**
Cash Generated from operations	(52,194.04)	13,607.24
Net Cash Flow from Operarting Activities	**(52,194.04)**	**13,607.24**
B: Cash Flow from Investing Activities		
Purchase of Fixed Assets	(93.00)	-
Capital Work in Progress	-	-
Capital Work In progress - R&D	(68,630.73)	(57,900.60)
Proceeds from sale of Fixed Assets	-	-
Investment in Subsidiaries	-	-
Purchase of other Non current Investments	-	-
Net Cash Flow from Investing Activites	**(68,723.73)**	**(57,900.60)**
C: Cash Flow from Financing Activites		
Increase /(Decrease) in Unsecured Loan		
Increase /(Decrease) in Working Capital	(42,093.91)	38,119.15
Increase /(Decrease) in Term Loan	1,18,162.99	12,792.50
Increase/(Decrease)Other Long Term Liabilities	12,500.00	-
Increase /(Decrease) in Share Capital	8,000.00	-
Increase /(Decrease) in Share Premium	32,000.00	-
Finance Charges	**(7,773.19)**	**(6,625.82)**
Net Cash Flow from Financing Activities	1,20,795.89	44,285.83
Actual Payment of Income Tax		
D: Net Increase/Decrease in Cash and cash Equivalents	(121.88)	(7.53)
Opening of Cash & Cash Equivalents	**1,476.48**	**1,484.01**
Closing Balance of Cash & Cash Equivalents	**1,354.60**	**1,476.48**

See accompanying notes to the financial statements
As per our report of even date annexed.

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board of Directors
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P.Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
Chief Financial Officer

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31st MARCH, 2026

Note : 1. CORPORATE INFORMATION

Vanta Bioscience Limited (“The Company”) was incorporated on 29thApril 2016. The company is engaged in the business of Preclinical Activities.

Vanta Bioscience Limited has one subsidiary and one step subsidiary. The details are as given below.

These Companies are engaged in Research & Development in the field of discovery and development of drugs, biological, vaccines, gene-based therapies as well as diagnostics and cosmetics including clinical research.

The list of subsidiaries considered in these financial statements with percentage of holding is as follows.

Name of the Subsidiary	Country of Incorporation	Percentage of Holding	Period of Consolidation
M/s. Vanta Clinical Research Limited	A wholly owned subsidiary of Vanta Bioscience Limited	100%	01.04.2025 to 31.03.2026

2. Summary of Significant Accounting Policies:

a. Basis of Preparation:

These Consolidated Financial statements have been prepared to meet the requirements under Section 133 of the Companies Act 2013 read with Companies (Accounts) Rules, 2015. The consolidated financial statements of Vanta Bioscience Limited and its subsidiaries (as listed above) collectively referred to as the 'Group', have been prepared and presented under the historical cost convention, on the accrual basis of accounting, in accordance with the provisions of the Companies Act,2013, to the extent considered necessary for the purpose of these accounts, and in accordance with the accounting principles generally accepted in India (' Indian GAAP') issued by the Institute of Chartered Accountants of India ('ICAI') , to the extent applicable. The financial statements are presented in Indian rupees rounded off to the nearest rupee.

The financial statements of the Company and its subsidiary have been combined on a line by line basis by adding together the book values of like items of assets, liabilities, income and expenses. Intra group balances and intra group transactions and resulting unrealized profits are eliminated in full. Unrealized losses resulting from intra group transactions are also eliminated unless cost cannot be recovered.

The Consolidated financial statements have been prepared using uniform accounting policies for like transactions and other events in similar circumstances.

All Assets and liabilities have been classified as current and non-current as per the Group's normal operating cycle and other criteria set out in Schedule III to the Companies Act.2013.

b. Principles of Consolidation:

The consolidated financial statements have been prepared in accordance with Indian Accounting Standard110 “Consolidated Financial statement” issued by the ICAI. The consolidated financial statements have beenprepared on the following basis:

I) The financial statements of the Parent company and its subsidiaries have been consolidated on a line-by-line basis by adding together the fair values of like items of assets, liabilities, income and expenses, after eliminating the intra-group balances/ transactions and resulting unrealized profits in full. Unrealized losses resulting from intra-group transactions have also been eliminated unless cost cannot be recovered, and are presented to the extent possible, in the same manner as the company's independent financial statements.

ii) The excess of cost to the parent company of its investment in the subsidiary over the parent company's portion of equity at the date on which investment in the subsidiary is made, is recognized as Goodwill(on consolidation). When the cost to the parent of its investment in the subsidiary is less than the parent company's portion of equity of the subsidiary at the date on which investment in the subsidiary is made, the difference is treated as Capital Reserve (on consolidation) in the consolidated financial statements.

iii) The financial statements of the subsidiaries used in the consolidation are drawn up to the same reporting date as that of the parent company i.e., period ended 31st March, 2026.

iv) Minority interestin the net assets of consolidated subsidiaries consists of the amount of equity attributable to the minority shareholders at the dates on which investments in the subsidiary companies are made and further movements in their share in the equity, subsequent to the dates of investments.

c. Use of Estimates:

The preparation of the consolidated financial statements requires the management of the Group to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to the contingent liabilities as at the date of the financial statements and reported amounts of income and expense during the year. Management believes that estimates made in the preparation of consolidated financial statements are prudent and reasonable. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in current and future periods.

d. Property, Plant& Equipment:

Fixed assets are stated at cost less depreciation. Cost includes freight, duties, taxes and incidental expenses related to acquisition and installation of the fixed assets. The expenses related to, and incurred during implementation period have been capitalized under the appropriate heads.

e. Depreciation:

Depreciation on Fixed assets has been charged on straight-line method at the rates and the manner specified in Schedule II to the Companies Act, 2013. The cost of plant materials including re-plantation expenses is being written off over a period of five years.

f. Inventories:

Inventories have been taken as valued and certified by the Management. The basis of valuation is as under:

Raw materials, Stores & Spares - at cost or net realizable value whichever is lower.

Finished goods – at cost or net realizable value on FIFO basis whichever is lower.

g. Revenue Recognition:

The company follows mercantile system of accounting and recognizes significant items of income and expenditure as and when they are incurred and accrued.

h. Retirement benefits:

1. Company's contribution to provident fund if any is charged to Profit & Loss Account.
2. Provision has been made in accounts for the future payment of gratuity to the employees of the Company. But the Company has not complied with the actuarial valuation requirements of Gratuity as per the Accounting Standard.

I. Investments:

Current Investments are valued at fair value. Long Term Investments are valued at fair value. The difference of Book Value and Fair Value is treated as Impairment Loss.

j. R&D Expenditure:

Capital expenditure is included in the fixed assets and depreciation as per Company's policy.

Revenue expenditure is charged to profit & loss account of the year in which they are incurred is included in the respective heads of expenditure.

k. Borrowing Costs:

Borrowings costs that are directly attributable to the acquisition of qualifying assets are capitalized as part of cost of such asset. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are charged to revenue.

l. Cash Flow Statement:

The Cash Flow Statement has been compiled from and is based on the Balance Sheet as at 31st March, 2026 and the related Profit and Loss Account for the year ended on that date. The Cash Flow Statement has been prepared under the indirect method as set out in the Indian Accounting Standard - 7 on Cash Flow statement issued by ICAI.

m. Accounting For Taxes On Income:

Current Tax: Provision for Current Income Tax is made on the basis of the taxable income for the year as determined in accordance with the provisions of Income Tax Act, 1961.

Deferred Tax: Deferred income tax is recognized, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. The tax effect is calculated on the accumulated timing differences at the year-end based on tax rates and laws. Enacted or substantially enacted as of the Balance Sheet date.

n. Employee Stock Option Scheme:

The company accounts for equity settled stock options as per the accounting treatment prescribed by Securities and Exchange Board of India (share based employee benefits) Regulations, 2014 and the Guidance Note on Employee Share-based Payments issued by the Institute of Chartered Accountants of India.

o. Impairment of Assets:

The management assesses using external and internal sources whether there is any indication that an asset may be impaired. Impairment of an asset occurs where the carrying value exceeds the present value of cash flow expected to arise from the continuing use of the asset and its eventual disposal. The provision for impairment loss is made when recoverable amount of the asset is lower than the carrying amount.

p. **Government Grants & Other Claims:**

Revenue grants including subsidy/rebates, refunds, claims etc., are credited to profit & loss account under other income or deducted from the related expenses. Grants related to fixed assets are credited to capital reserves account or adjusted in the cost of such assets as the case may be, as and when the ultimate realisability of such grants etc., are established/realized.

q. **Provisions and Contingent Liabilities and Contingent Assets:**

Provisions in respect of present obligations arising out of past events are made in the accounts when reliable estimate can be made of the amount of obligations and it is probable that there will be an outflow of resources. Contingent Liabilities are not recognized but if material, are disclosed in the notes to accounts. Contingent assets are not recognized or disclosed in the financial statements.

r. **Cash and Cash Equivalents:**

Cash and cash equivalents comprise of cash at bank and cash in hand. The Company considers all highly liquid investments with an original maturity of three months or less from date of purchase, to be cash equivalents.

s. **Leases:**

Lease rentals in respect of assets acquired under operating lease are charged to Statement of Profit and Loss.

t. **Intangible Assets:**

The expense incurred on the development of overseas markets has been recognized as Intangible Assets and will be amortized over a period of five years. The company is following the practice of writing off Deferred Revenue Expenses over a period of five years and the same accounting treatment is consistently followed for the current year also. Any new deferred revenue expenditure incurred will be written off in the year of such expenditure as per Indian Accounting Standard 38.

u. **Segment Reporting:**

The accounting policies adopted for segment reporting are in conformity with the accounting policies adopted for the company. Further,

(I) Inter segment revenue has been accounted for based on the transaction price agreed to between segments which is primarily market based.

(ii) Revenue and expenses have been identified to segments on the basis of their relationship to the operating activities of the segment. Revenue and expenses, which relate to the company as a whole and are not allocable to segments on a reasonable basis, have been included under “Un-allocated corporate expenses net of un-allocated income”.

v. **Foreign Currency transactions:**

Transactions in foreign currency are recorded at the exchange rate prevailing on the date of the transaction. Net exchange gain or loss resulting in respect of foreign exchange transactions settled during the period is recognized in the profit and loss account except for the net exchange gain or loss on account of imported fixed assets, which is adjusted in the carrying amount of the related fixed assets. Foreign currency denominated current assets and current liabilities at period end are translated at the period end exchange rates and the resulting net gain or loss is recognized in the profit and loss account, except for exchange differences related to acquisition of fixed assets purchased from foreign countries is adjusted in the carrying amount of the related fixed assets.

w. **Foreign Currency translation:**

The consolidated financial statements are reported in Indian rupees. Since the company has the non-integral subsidiaries, assets and liabilities are translated at exchange rates prevailing at the date of the Balance sheet. The items in the Profit and loss account are translated at the average exchange rate during the period. The differences arising out of the transactions are transferred to Exchange translation reserve on consolidation of non-integral subsidiary, under Reserves and Surplus.

x. **Earnings per share:**

The basic earnings per equity share is computed by dividing the net profit or loss for the period attributable to the equity shareholders by the weighted average number of equity shares outstanding during the reporting period. The number of shares used in computing diluted earnings per share comprises the weighted average number of shares considered for deriving basic earnings per share, and also the weighted average number of equity shares, which may be issued on the conversion of all dilutive potential shares, unless the results would be anti-dilutive.

Note No: 3 Share Capital

Particulars	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	Rupees in Thousands	No. of Shares	Rupees in Thousands
a) Share Capital				
Authorized	75,00,000	75,000.00	75,00,000	75,000.00
Equity Shares of Rs. 10 Each				
Issued, Subscribed and fully paid up	71,12,000	71,120.00	63,12,000	63,120.00
Equity Shares of Rs. 10 Each				
Total	**71,12,000**	**71,120.00**	**63,12,000**	**63,120.00**

b) Reconcilation of the number of shares and amount outstanding at the beginning and at the end of the reporting period

Particulars	As at 31.03.2025		As at 31.03.2024	
	No. of Shares	Rupees in Thousands	No. of Shares	Rupees in Thousands
Equity Shares outstanding at the beginning of the year	63,12,000	63,120.00	63,12,000	63,120.00
Equity Shares Issued during the year	8,00,000	8,000.00	-	-
Total	**71,12,000**	**71,120.00**	**63,12,000**	**63,120.00**

c) Terms/ Rights attached to Equity Shares

The company has only one class of equity shares having par value of Rs. 10 Per share. Each holder of equity share is entitled to one vote per share.

d) Details of share held by each share Holder holding more than 5% Equity Shares

Name of the Share holder	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	Rupees in Thousands	No. of Shares	Rupees in Thousands
Mulakala Mohan krishna	34,85,500	34,855.00	34,85,500	34,855.00
Mulakala Dopesh Raja	8,58,000	8,58,000	4,58,000	4,580.00
S CHANDRA SEKHAR RAO	5,22,500	5,22,500	-	-
Total	**48,66,000**	**39,435.00**	**39,43,500**	**39,435.00**

e) Details of shares held by promoters at the end of the year along with % of change

Name of the Promoter	As at 31.03.2026		As at 31.03.2025	
	No. of Shares	% of total shares	No. of Shares	% of total shares
MOHAN KRISHNA MULAKALA	3485500	49.01	34,85,500.00	55.22
PRADEEP CHOWDARY VEERAMACHINENI	21500	0.30	21,500.00	0.34
DOPESH RAJA MULAKALA	858000	12.06	4,58,000.00	7.26
VYASMURTI MADHAVRAO SHINGATGERI	50000	0.70	50,000.00	0.79
MULAKALA KARISHMA	50100	0.70	50,100.00	0.79
SHRAVAN CHINTAPATLA	80100	1.13	80,100.00	1.27
S CHANDRA SEKHAR RAO	522500	7.35	1,22,500.00	1.94
M SAJAN KIRAN	20100	0.28	20,100.00	0.32
SOUMYA SIMHADRI	90100	1.27	90,100.00	1.43
SUJANA SHEELA MULAKALA	100	0.00	100.00	0.00

4. Reserves & Surplus

Particulars	As at 31.03.2026	As at 31.03.2025
Share Premium	1,84,120.00	1,52,120.00
General Reserve		
Balance as per the last Balance Sheet	-	-
Add: transferred during the Year	-	-
Surplus in Profit & Loss Statement		
Balance as per the last Balance Sheet	-44,566.41	-17,857.81
Add: transferred during the Year	1,082.55	-26,708.60
Total	**1,40,636.14**	**1,07,553.59**

5. Deferred Tax Liability

Particulars	As at 31.03.2026	As at 31.03.2025
Deferred Tax Liability	6,481.52	7,427.05
Deferred Tax Liability	**6,481.52**	**7,427.05**

6. Long Term Borrowings

Particulars	As at 31.03.2026	As at 31.03.2025
Term Loan		
From Banks and from Financial Institutions		
Secured Borrowings		
Term Loan	40,625.88	92,451.22
Unsecured Loans		
Loans from Directors and Related parties	3,12,076.16	1,54,128.00
Unsecured Borrowings		
Less: Amount disclosed under the head Short Term Borrowings payable with in 1 year	40,625.88	52,666.05
Total	**3,12,076.16**	**1,93,913.17**

a. Term Loan from State bank of India, SME Branch, Saifabad is secured by the hypothecation of Plant & Machinery including Lab Equipment standing in the name of the Company and primary security of Plot No. K2 11th Cross, SIPCOT, Industrial Complex, Gummidipudi, Tamilnadu-601201

b. Collateral Security of Module A123 Quatrant3, 5th Floor, Cyber Towers, Madhapur, Serlingampally, Rangareddy-500050 and Personal Gurantee of two directors Mr. Mulakala Mohan Krishna and Mr.Mulakala Dopesh Raja

7. Other Long Term Liabilities

Particulars	As at 31.03.2026	As at 31.03.2025
Security Deposits	12,500.00	-
Total	**12,500.00**	**-**

8. Short Tem Borrowings

Particulars	As at 31.03.2026	As at 31.03.2025
Unsecured Loans		
Secured Loans		
Cash Credit Loan	25,142.35	25,285.39
Working Capital Demand Loan	2,937.93	2,990.54
SBI TOD Loan A/c No.42307725188	-	29,858.09
Current Maturity on Term Loan	40,625.88	52,666.05
Total	**68,706.16**	**1,10,800.07**

The Cash Credit and Working Capital Demand Loan from State Bank of India, SME Branch, Saifabad is secured by way of hypothecation of Stocks, Book Debts, first charge on movable fixed assets and further guranteed by the directors.

8. Trade Payables

Particulars	As at 31 Mar, 2026				
	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Dues - MSME	-	-	-	-	-
Undisputed Dues - Others	4,965.09	1,164.13	1,440.32	8,519.66	16,089.20
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-
Total	**4,965.09**	**1,164.13**	**1,440.32**	**8,519.66**	**16,089.20**

Particulars	As at 31 Mar, 2025				
	Outstanding for following periods from due date of payment				
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Dues - MSME	-	-	-	-	-
Undisputed Dues - Others	11,499.52	5,194.93	3,632.55	16,651.02	36,978.02
Disputed Dues - MSME	-	-	-	-	-
Disputed Dues - Others	-	-	-	-	-
Accrued Expenses					
Total	**11,499.52**	**5,194.93**	**3,632.55**	**16,651.02**	**36,978.02**

10. Other Current Liabilities

Particulars	As at 31.03.2026	As at 31.03.2025
Outstanding Interest on Term Loan	474.54	2,468.36
Outstanding Interest on GEC Loan	-	520.07
Outstanding Interest on Addl GEC Loan	31.27	360.58
Creditors for Capital Goods	8,500.81	8,733.37
Salaries & Wages Payable	9,756.34	12,761.07
Interest Payable on Unsecured Loan	7,493.07	17,953.63
Statutory Liabilities Payable	7,160.76	5,164.61
Total	**33,416.79**	**47,961.69**

12. Long Term Investments

Particulars	As at 31.03.2026	As at 31.03.2025
Investment in Vanta Clinical Research Limited [30,00,000 Shares of Rs. 10/- each (30,00,000 Shares of Rs. 10/- each) stated at cost]	30,000.00	30,000.00
Total	**30,000.00**	**30,000.00**

13. Long Term Loans and Advances

Particulars	As at 31.03.2026	As at 31.03.2025
Loan to Cebis India Ltd (formerly Vayam ResearchSolutions Limited)	8,839.94	8,839.94
Total	**8,839.94**	**8,839.94**

NOTE 11 PROPERTY, PLANT & EQUIPMENT

(Fig. in Rupees)

DESCRIPTION	GROSS BLOCK					DEPRECIATION						NET BLOCK	
	As on 01-04-2025	During the Year		Capitalisation of Preoperative Expenses	Total as on 31-03-2026	As on 01-04-2025	For the Year 31-03-2026	Depreciation transferred to Procees under Development	Depreciation charged to Profit & Loss	Adjustments/ Deletions	Total as on 31-03-2026	As on 31-03-2026	As on 31-03-2025
		Additions	Deletions										
Tangible Assets:													
LAND	11,750.80	-	-	-	11,750.80	-	-	-	-	-	-	11,750.80	11,750.80
BUILDING	60,017.24	-	-	-	60,017.24	14,679.87	1,900.55	1,520.44	380.11	-	16,580.42	43,436.82	45,337.37
PLANT & MACHINERY	31,272.00	-	-	-	31,272.00	14,648.60	1,980.56	1,584.45	396.11	-	16,629.16	14,642.84	16,623.40
LAB EQUIPMENT	59,455.78	52.00	-	-	59,507.78	33,508.48	5,650.59	4,520.47	1,130.12	-	39,159.07	20,348.71	25,947.30
MISC. FIXED ASSETS	1,543.19	-	-	-	1,543.19	1,107.40	146.60	-	146.60	-	1,254.00	289.19	435.79
COMPUTERS	4,473.90	41.00	-	-	4,514.90	4,435.68	23.01	-	23.01	-	4,458.69	56.21	38.22
ELECTRICAL EQUIPMENT	10,515.87		-	-	10,515.87	7,587.01	999.04	799.23	199.81	-	8,586.05	1,929.82	2,928.86
FURNITURE & FITTINGS	16,857.16		-	-	16,857.16	10,941.27	1,601.43	-	1,601.43	-	12,542.70	4,314.46	5,915.89
Capital Work in Progress	-	-	-	-	-	-	-	-	-	-	-	-	-
TOTAL	**1,95,885.94**	**93.00**	**-**	**-**	**1,95,978.94**	**86,908.31**	**12,301.78**	**8,424.59**	**3,877.19**	**-**	**99,210.09**	**96,768.85**	**1,08,977.63**
Previous Year													
Intangible Assets:													
Research & Development	3,15,370.83	68,630.73	-	-	3,84,001.56	-	-				-	3,84,001.56	3,15,370.83
TOTAL	**3,15,370.83**	**68,630.73**	**-**	**-**	**3,84,001.56**	**-**	**-**	**-**	**-**		**-**	**3,84,001.56**	**3,15,370.83**
Previous Year	**2,57,470.23**	**57,900.60**	**-**	**-**	**3,15,370.83**	**-**	**-**	**-**	**-**		**-**	**3,15,370.83**	**2,57,470.23**

14. Other Non Current Assets

Particulars	As at 31.03.2026	As at 31.03.2025
Electricity Deposit	94.22	94.22
Security Deposits	-	-
Other Deposits with Banks	-	-
Total	**94.22**	**94.22**

15. Inventories

Particulars	As at 31.03.2026	As at 31.03.2025
Services / Method Under Process	74,930.38	64,592.58
Closing Stock of Material	344.22	234.18
Total	**75,274.60**	**64,826.76**

16. TRADE RECEIVABLES

Particulars	As at 31 Mar, 2026					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables - Considered Good						
Undisputed Trade Receivables - Considered Doubt	5,112.42	1,908.17	5,199.27	8,826.60	4,537.05	25,583.51
Disputed Trade Receivables - Considered Good						-
Disputed Trade Receivables - Considered Doubt						-
Total	**5,112.42**	**1,908.17**	**5,199.27**	**8,826.60**	**4,537.05**	**25,583.51**

Particulars	As at 31 Mar, 2025					
	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1 Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables - Considered Good	450.10	4,760.33	8,041.25	3,005.60	1,190.25	17,447.53
Undisputed Trade Receivables - Considered Doubt						-
Disputed Trade Receivables - Considered Good						-
Disputed Trade Receivables - Considered Doubt						-
Total	**450.10**	**4,760.33**	**8,041.25**	**3,005.60**	**1,190.25**	**17,447.53**

17. Cash & Cash Equivalents

Particulars	As at 31.03.2026	As at 31.03.2025
In current Accounts	62.32	62.97
Cash on Hand	1,292.28	1,413.51
Total	**1,354.60**	**1,476.48**

18. Short Term Loans & Advances

Particulars	As at 31.03.2026	As at 31.03.2025
Advances to Creditors	5,737.40	4,459.89
Advance for Expenses	-	-
Staff Advance-Salary	44.53	521.18
Other Advances	27,265.45	9,695.52
GST Input Credit	728.75	1,320.05
Interest Accrued	-	-
TDS Receivable	-	-
Total	**33,776.13**	**15,996.64**

19. Other Current Assets

Particulars	As at 31.03.2026	As at 31.03.2025
Prepaid Expenses	334.62	241.78
IT Refund	754.65	238.49
MAT Credit	4243.29	4243.29
Total	**5332.56**	**4,723.56**

20. Revenue from Operations

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Revenue from Testing Analysis Service Charges(Domestic)	15,642.06	2,517.38
Revenue from Testing Analysis Service charges(Export)	2,305.68	8,756.84
Sale of Products	215.90	-
Total	**18,163.64**	**11,274.22**

21. Other Income

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Interest Income	-	-
Other Income	9.96	41.61
Foreign Exchange Fluctuation	1,584.91	350.14
Total	**1,594.87**	**391.75**

22. Consumption of Material

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Opening Stock of materials	234.18	359.89
Add: Purchases	**-**	**-**
Purchase of Lab chemicals	85.38	40.86
Feed Cost	599.01	148.65
Purchase of Consumables	815.10	240.15
Purchase of Live Animals	9.10	161.75
Testing Charges	13.94	17.80
Sub Total	**1,756.71**	**969.10**
Less: Closing Stock	344.22	234.18
Total	**1,412.49**	**734.92**

23. Change in Inventory-Work in Progress

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Opening Method and process	64,592.58	74,487.96
Less: Closing Method and process	74,930.38	64,592.58
Total	**(10,337.80)**	**9,895.38**

22. Employment Benefit Expenses

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Salaries & Wages	4,880.14	4,790.35
Director Remuneration	-	-
Staff Welfare Expenses	151.33	289.06
Contribution to PF	137.20	177.36
Contribution to ESI	16.20	12.73
Leave Encashment	383.31	-
Gratuity	172.96	-
Labour Charges	373.33	558.36
Total	**6,114.47**	**5,827.86**

25. Finance Cost

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Interest on Cash Creidt	764.26	754.56
Interest on Term Loan	1,709.32	2,455.68
Interest on Working Capital Term Loan	201.76	455.75
Interest on GECL Loan	151.87	493.38
Interest on Others	491.03	8.30
Interest on Unsecured Loan	3,778.03	2,194.92
Interest on Loan taken	-	-
Bank Charges	33.86	81.51
Loan Processing Fee	643.06	181.72
Total	**7,773.19**	**6,625.82**

26. Depreciation and Amortisation Expenses

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Depreciation	3,877.19	4,400.57
Total	**3,877.19**	**4,400.57**

25. Other Expenses

Particulars	For the Year ended 31.03.2026	For the Year ended 31.03.2025
Factory Maintenance	64.64	86.52
Lab Maintenance	130.23	175.43
Repairs & Maintenance - P&M	171.19	283.68
Repairs & Maintenance - Others	162.39	241.54
Diesel Charges	131.28	221.69
Electricity Charges	1,685.12	2,295.30
Rent	127.44	127.44
Audit Fee	-	-
Statutory Audit Fee	200.00	200.00
Internal Audit Fee	100.00	100.00
Audit Expenses	-	10.84
Business Development Expenses	233.49	1,795.20
Commission	931.28	335.34
Computer Expenses	191.29	182.48
Consultancy Charges	2,671.98	788.00
Conveyance	154.99	214.16
General Expenses	567.70	424.61
Insurance	207.33	205.56
Internet expenses	28.00	26.28
Legal Expenses	-	-
Office Maintenance	0.75	108.11
Other Expenses	0.65	-
Postage & Telegrams	63.09	61.99
Printing & Stationery	31.76	85.20
Professional Charges	-	-
Rates & Taxes	297.36	389.72
Registration & Renewals	1.00	21.50
Safety Expenses	121.63	267.06
Security Expenses	700.05	743.83
Staff Recruitment Expenses	5.60	11.78
Subscription & Membership Fee	274.91	356.33
Telephone Expenses	31.93	44.02
Travelling Expenses	1,003.26	1,081.84
Vehicle Hire charges	436.91	600.26
Other Expenses	-	0.80
Bad Debts	-	-
Prior Period Items	-	-
Carriage Outward - Local	54.70	-
Total	**10,781.95**	**11,486.51**

Note No. 28 : FINANCIAL RATIOS

Sl. No.	Ratio	Numerator	Denominator	2026	2025	% Variance	Reasons for variance of above 25%
1	Current Ratio (in times)	Current Assets	Current Liabilities	1.20	0.53	123.99	Variance is primarily on account of increase in current assets and decrease in current liabilities.
2	Debt - Equity Ratio (in times)	Total Debt	Total Equity	1.80	1.79	0.72	-
3	Debt Service Coverage Ratio (in times)	Earnings available for Debt Service	Debt Service	0.12	-0.41	-128.63	Variance is primarily on account of increase in profit and decrease in debt serviced.
4	Return on Equity Ratio (in %)	Profit After Tax	Average Equity	1.52	-42.31	-103.60	Variance is primarily on account of increase in profit.
5	Inventory Turnover Ratio (in times)	Net Sales	Average Inventory	NA	NA	NA	-
6	Trade Receivables Turnover Ratio (in times)	Revenue from Operations	Average Trade Receivables	0.71	0.65	9.87	-
7	Trade Payables Turnover Ratio (in times)	Adjusted Expenses	Average Payables	0.09	0.02	474.39	Variance is primarily on account of increase in Adjusted expenses and decrease in trade payables.
8	Net Capital Turnover Ratio (in times)	Revenue from Operations	Average Working Capital (i.e. Total current assets less Total current liabilities)	0.79	-0.12	-736.29	-
9	Net Profit Ratio (in %)	Profit After Tax	Revenue from Operations	5.96	-	-102.52	Variance is primarily on account of increase in Revenue and profits.
10	Return on Investment (in %)	Income generated from Investments	Average Investments	NA	NA	NA	-
11	Return on Capital Employed (in %)	Profit before tax and finance costs	Capital Employed = Net Worth + Lease Liabilities + Deferred Tax Liabilities	3.62	-11.61	-131.22	Variance is primarily on account of increase in profits and networth.

29. In the view of Management, no event has taken place to trigger the need for testing its assets for impairment. Accordingly, as per the management assessment, the carrying values of its assets as at the Balance sheet date are not higher than their corresponding recoverable amounts.

30. FOREIGN EXCHANGE TRANSACTIONS

Rupees in Thousands

	Particulars	31 March 2026
A	Expenditure on Foreign Currency	NIL
B	Earnings on Foreign Currency	2,305.68
C	Foreign Exchange Loss	1584.91

31. CONTINGENT LIABILITIES: NIL

32. AUDITOR'S REMUNERATION:

Rupees in Thousands

Particulars	31 March 2026	31 March 2025
A. Statutory Auditor:		
Statutory Audit Fee	175.00	
Tax Audit Fee	25.00	
Total A		200.00
B. Internal Auditor:		
Internal Auditor Fee	100.00	
Total B		100.00
Total (A) and (B)		**300.00**

33. MANAGERIAL REMUNERATION: NIL

34. EARNING PER SHARE (EPS):

Particulars	Period Ended 31 March 2026	Period Ended 31 March 2025
Profit attributed to the Equity Shareholders (Rupees in Thousands) (A)	1,082.55	(26,708.60)
Weighted average number of Equity Shares Outstanding during the year (B)	71,12,000	63,12,000
Face Value of Equity Shares (Rs)	10/-	10/-
Basic Earnings per share (Rs.) - (A/B)	0.15	(4.23)
Diluted Earnings per Share (Rs.) (A/B)	0.15	(4.23)

35. OPERATING SEGMENTS:

The Company is engaged in the business of Preclinical Activities and is not engaged in any other kind of business. Hence segment reporting is not applicable.

34. RELATED PARTY TRANSACTIONS:

Disclosure as required by Accounting Standard AS 18: Related partydisclosures issued by the Institute of Chartered Accountant of India (ICAI) are as follows:

S. No.	Name of the Related Party	Relation	Nature of Transaction	Volume of Transaction (Rupees in Thousands)	Closing Balance as on 31/03/2026 (Rupees in Thousands)
VANTA BIOSCIENCE LIMITED (HOLDING COMPANY)					
1.	Sarvotham Care	Promoter Director is the proprietor of the firm	Unsecured Loan received by the Company	0.00	800.00
2.	M. Sujana Sheela	Promoter's Spouse	Office Rent	63.72	504.65
3.	Sarvotham Remedies Limited	Promoter Directors are Directors of the Company	Unsecured Loan received by the Company & Interest on Loan	Nil & 1650.00	16,500.00 & Nil
4.	Sarvotham Solutions Limited	Promoter Directors are Directors of the Company	Unsecured Loan received by the Company & Interest on Loan	Nil & 3064.80	30,648.00 & Nil
5.	Sarvotham Care Limited	Promoter Directors are Directors of the Company	Unsecured Loan received by the Company & Interest on Loan	191,848.16 & 12,688.07	241,913.16 & 174.04
6.	Cebis India Limited	Step Subsidiary	Expenses of the Company incurred by Cebis India Limited	40,497.88	26,856.92
7.	Vanta Clinical Research Limited	Subsidiary Company	Repayment by the company	-	9,500.94
8.	Sri. M. Dopesh Raja	KMP	Unsecured Loan received by the Company & 4,00,000 Shares issued @ Rs. 50/- per share	6,100.00 & 20,000.00	20,000.00
9.	D V S Murali	KMP	Key Managerial Personal Compensation	442.79	67.60
10.	Sangeetha Padam Choudhary	KMP	Key Managerial Personal Compensation	210.00	0.00
11.	Pooja Kothari	KMP	Key Managerial Personal Compensation	60.00	30.00
12.	Simhadri Chandra Sekhar Rao	KMP	Unsecured Loan received by the Company 4,00,000 Shares issued @ Rs. 50/- per share & Interest on Loan	Nil 20,00,000 & 1,487.26	12,900.00 & 7,319.04
VANTA CLINICAL RESEARCH LIMITED (SUBSIDIARY COMPANY)					
1.	CEBIS India Limited		Loans& Advances, Interest Receivable and Other Payable	Nil, Nil and 10.15	8,839.94, 408.53 and 10.15

35. DEFERRED TAX: **Rupees in Thousands**

Particulars	31 March 2026
In Conformity with the Accounting Standard 22 on Accounting for Taxes on income issued by Institute of Chartered Accountants of India, during the year the Company has provided for the Net Deferred Tax Liability/ Assets in the books of account.	
Net Block as per Companies Act	96,768.85
Net Block as per Income Tax Act	71,839.94
Timing Difference	24,928.91
Net Tax Liability as on 31-03-2026	6,481.52
Less: Deferred Tax Liability as on 31-03-2025	7,427.04
Effect on Profit and Loss Account (Deferred Tax Income for the year)	945.53

#Deferred Tax liability represents timing differences in depreciation on fixed assets.

38. In the opinion of the Board the Current assets, Loans and advances are approximately of the value stated if realized in the ordinary course of the business. The provision for depreciation and all known liabilities are adequate and not in excess of the amount considered reasonably necessary.

39. Confirmation of balances has not been received from any of the Creditors, Debtors and for Loans & Advances, which are subject to reconciliation. Provision for doubtful debts, if any, in respect of the above and the consequential adjustment, if any, whether of revenue nature or otherwise, will be dealt accordingly.

40. DISCLOSURE UNDER MICRO, SMALL AND MEDIUM ENTERPRISES DEVELOPMENT ACT, 2006:

As regards to the compliance of provisions relating to the dues to Micro, Small and Medium Enterprises in terms of Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006, the Company has sent letters to the Creditors to confirm whether they are Micro, Small and Medium Enterprises. The Company is yet to receive the confirmations from them. Hence, the Company could not quantify the dues, if any to the Micro, Small and Medium Enterprises.

Particulars	For the Year ended March 31, 2026		For the Year ended March 31, 2025	
	Principal	Interest	Principal	Interest
Amount due to Vendor	Nil	Nil	Nil	Nil
Principal amount paid (includes unpaid) beyond the appointed date	Nil	Nil	Nil	Nil
Interest due and payable for the period	Nil	Nil	Nil	Nil
Interest accrued and remaining paid	Nil	Nil	Nil	Nil

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of the information collected by management.

41. Additional information pursuant to Part II of Schedule III of the Companies Act, 2013. Quantitative and other details: Not Applicable.

42. During the year the following provisions are made:

Current Tax - Nil

43. Information on Net Assets and Share of Profits as at March 31, 2026:

Name of the Entity	Net Assets (Total Assets less Total Liabilities)		Share in Profit & Loss	
	As % of Consolidated Net Assets	Amount in Rupees	As % of Net Profits	Amount in Rupees
Parent				
Vanta Bioscience Limited	100.37%	2,12,531.80	110.68%	1,198.11
Subsidiaries				
Vanta Clinical Research Limited	(0.37)%	(775.67)	(10.68)%	(115.57)
Minority Interest		Nil	Nil	Nil

Information on Net Assets and Share of Profits as at March 31, 2025

Name of the Entity	Net Assets (Total Assets less Total Liabilities)		Share in Profit & Loss	
	As % of Consolidated Net Assets	Amount in Rupees	As % of Net Profits	Amount in Rupees
Parent Vanta Bioscience Limited	100.39%	1,71,333.69	99.57%	(26,594.08)
Subsidiaries Vanta Clinical Research Limited	(0.39)%	(660.11)	0.43%	(114.52)
Minority Interest		Nil	Nil	Nil

44. The Subsidiary of the Company has not yet started its operations till the date of this report.

45. No Provision for Gratuity has been created in the case of Holding and Subsidiary Company.

46. The cash balance of Holding Company as on 31.03.2026 amounts to Rs.1,292.28 Thousands. Since we could not undertake physical verification of cash on 31.03.2026 we have relied upon the certificate issued by the management in this regard.

47. An amount of Rs. 68,630.73 Thousands was spent towards Research & Development in Holding company during the year under review.

48. The company has not proposed any dividend for the year under review.

49. Previous year figures have been regrouped and rearranged wherever necessary.

50. Figures have been rounded off to the nearest thousands.

As per our attached report of even date

For **Mathesh & Ramana**
Chartered Accountants

For and on behalf of the Board
Vanta Bioscience Limited

Sd/-
B. V. Ramana Reddy
Partner
M. No. 026967

Sd/-
M. Dopesh Raja
Managing Director
DIN: 01176660

Sd/-
P. Venkata Appaji
Director
DIN: 02614167

Place: Hyderabad
Date : 30.05.2026

Sd/-
Pooja Kothari
Company Secretary

Sd/-
DVS Murali
Chief Financial Officer

VANTA BIOSCIENCE LIMITED
CIN: L74999TG2016PLC109280
Address: No.02/G/308/G NO.3/FF/SF/1-20-248, Umajay Complex Rasoolpura,
Secunderabad – 500003, Telangana
Tel No.: +91 40 6657 5454, **Email ID:** cs@vantabio.com

ATTENDANCE SLIP FOR ANNUAL GENERAL MEETING

10th Annual General Meeting

(Please complete this attendance slip and hand it over at the entrance of the registered office)

I/ We hereby record my/ our presence at the 10th Annual General Meeting of the Company held on Wednesday, September 30, 2026 at 10:00 AM at 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad – 500009, Telangana.

Name of the Member/Proxy____________________ Signature____________________

Folio No.____________________ No. of Shares Held____________________

*DP ID____________________ *Client ID____________________

*Applicable to investors holding shares in Electronic Form

Notes:

1. Electronic copy of the Annual Report for 2026 and Notice of the Annual General Meeting along with Attendance Slip and Proxy Form is being sent to all the members whose email address is registered with the Company/ Depositary Participant unless any member has requested for a hard copy of the same. Shareholders receiving electronic copy and attending the Annual General Meeting can print copy of this Attendance Slip.

VANTA BIOSCIENCE LIMITED
CIN: L74999TG2016PLC109280
Address: No.02/G/308/G NO.3/FF/SF/1-20-248, Umajay Complex Rasoolpura,
Secunderabad – 500003, Telangana
Tel No.: +91 40 6657 5454, **Email ID:** cs@vantabio.com

FORM NO. MGT-11
PROXY FORM

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Name of the Member(s):	
Registered Address:	
E-mail ID:	
Folio No/ Client ID:	
DP ID:	No. of Shares Held:

I/We, being the member(s) of ___________ shares of the above named company, hereby appoint

1.	Name:	
	Address	
	Email ID	Signature
	Or failing him	
2.	Name:	
	Address	
	Email ID	Signature
	Or failing him	
3.	Name:	
	Address	
	Email ID	Signature
	Or failing him	

as my/ our proxy to attend and vote (on poll) for me/ us and on my/ our behalf at the 10th Annual General Meeting of the Company held on Wednesday, September 30, 2026 at 10:00 A.M. at 197, Arun Khetarpal Rd, Uma Nagar Colony, Sikh Village, Bowenpally, Secunderabad - 500009, Telangana and at any adjournment thereof in respect of such resolutions as are indicated below:

Sl.No.	Resolution	For	Against
1.	To receive, consider and adopt the Audited Standalone and Consolidated Financial Statements for the financial year ended March 31, 2026 along with the Reports of the Auditors and Board of Directors thereon.		
2.	To appoint a director in place of Mr. Dopesh Raja Mulakala (DIN: 01176660), Managing Director of the Company, who retires by rotation and being eligible, offers himself for re-appointment.		
3.	Re-appointment of Mr. Dopesh Raja Mulakala (DIN: 01176660) as Managing Director of the Company.		

Please put a tick mark (3) in the appropriate column against the resolutions indicated in the box. If a member leaves the "For" or "Against" column blank against any or all the Resolutions, the proxy will be entitled to vote in the manner he/she thinks appropriate. If a member wishes to abstain from voting on a particular resolution, he/she should write "Abstain" across the boxes against the Resolution.

Affix
Revenue
Stamp

Signed this ………… day of ………………. 2026

Signature of Member

Signature of Proxy holder(s):

FORM FOR REGISTRATION OF EMAIL ADDRESS FOR RECEIVING DOCUMENTS/NOTICES BY ELECTRONIC MODE

To.

Bigshare Services Private Limited
RTA of Vanta Bioscience Limited
306, Right Wing, Amrutha Ville Apts. Somajiguda, Hyderabad - 500 082
Contact No. : 040 2337 4967

Sub: Registration of email address for receiving documents/notices by electronic mode Ref: Vanta Bioscience Limited - Scrip Code: 540729 – ISIN: INE695X01011

I agree to receive all documents/notices and other correspondences and communications including the annual report from the Company in electronic mode. Please register my email address given below in your records for sending communication through email.

The following are my details Name of Sole/First Holder:

DP ID Client ID/ Regd. Folio No:

PAN No.:

Email Address: Phone No.

I request you to kindly update the same in your records. I instruct you to send all documents/notices and other correspondences and communications including annual report from the Company in electronic mode to the email id mentioned above.

Name: ________________________

Signature: _____________________

Date:

Place:

ROUTE MAP


Miyapur
మియాపూర్
JEEDIMETLA
జీడిమెట్ల
Cheeriyal
చీరియాల్
44
65
KUKATPALLY
కుకట్పల్లి
Sarvotham
Remedies Limited
Kondapur
కొండాపూర్
MADHAPUR
మాదాపూర్
Secunderabad
సికింద్రాబాద్
Manikonda
Jagir
163

SCIENCE
FOR A
HEALTHIER
TOMORROW

If undelivered, please return to

Registered Office :

VANTA BIOSCIENCE LIMITED
No.02/G/308/G, No.3/FF/SF/1-20-248,
Umajay Complex, Rasaolpura,
Secunderabad - 500 003, Telangana, India
CIN: L74999TG2016PLC109280
Contact No.: +91 40 6657 5454
Website: www.vantabio.com
Email ID: cs@vantabio.com